The Role Of Aldh1A2 In Head And Neck Squamous Cell Carcinoma by Horstmann, Abigail
	
	
THE ROLE OF ALDH1A2 IN HEAD AND NECK SQUAMOUS CELL 
CARCINOMA 
 
 
A Dissertation 
Presented to the Faculty of the Weill Cornell Weill Graduate School 
of Medical Sciences 
in Partial Fulfillment of the Requirements for the Degree of  
Doctor of Philosophy 
 
 
by 
Abigail Kathryn Horstmann 
June 2017 
  
	
	
 
 
 
 
 
 
 
 
© 2017 Abigail Kathryn Horstmann 
	
	
THE ROLE OF ALDH1A2 IN HEAD AND NECK SQUAMOUS CELL 
CARCINOMA 
Abigail Kathryn Horstmann, Ph.D. 
Cornell University 2017 
 
Head and neck squamous cell carcinomas (HNSCC) are one of the most 
common cancers worldwide. The patient 5-year survival rate has remained 
approximately 50% for decades, necessitating discovery of novel therapies and targets. 
To date, all-trans retinoic acid (RA) and its isoforms – retinoids – are some of the 
most-studied and most-active agents in the treatment and prevention of HNSCC. A 
key enzyme involved in catalyzing the synthesis of endogenous RA from retinol 
(vitamin A), aldehyde dehydrogenase 1a2 (ALDH1a2), has previously been shown to 
act as a tumor suppressor in human prostate cancer. Among HNSCC patients, high 
ALDH1a2 protein expression correlates with better overall survival. Our primary 
objective was to delineate the role of ALDH1a2 in HNSCC carcinogenesis; further 
study into the proteins involved in endogenous retinoid synthesis and signaling, such 
as ALDH1a2, could reveal new and more effective strategies for retinoid therapy. We 
found that ALDH1a2 transcript levels are dramatically reduced in RNA data sets from 
over 300 human HNSCC samples, as well as in SCC tumor tissue from mice subjected 
to the 4-nitroquinoline 1-oxide (4-NQO)-induced murine model of human oral 
carcinogenesis developed in our lab. Through retroviral gene transduction, we 
overexpressed ectopic ALDH1a2 in human HNSCC cell lines SCC-4, SCC-9, and 
SCC-25. We observed that ALDH1a2 overexpression affects the phenotype of these 
transformed cells in vitro, decreasing both proliferation and clonogenicity. In addition, 
we created transgenic mice that inducibly express transgenic ALDH1a2 specifically in 
select, stratified epithelial tissues including the tongue, skin, and esophagus. These 
	
	
mice underwent 4-NQO treatment, to determine whether ectopic ALDH1a2 
expression can suppress oral cavity carcinogenesis in vivo. We found that the 
expression of ectopic ALDH1a2 during 4-NQO-induced carcinogenesis reduced the 
tongue protein expression of enhancer of zeste homolog 2 (EZH2) and vimentin, two 
markers of epithelial-to-mesenchymal transition (EMT) and tumor migration in this 
disease. This work provides evidence that ALDH1a2 has tumor suppressive functions 
in HNSCC and has furthered our understanding of retinoid signaling and cancer 
chemoprevention. 
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CHAPTER ONE 
INTRODUCTION 
 
HEAD AND NECK CANCER 
Incidence and overview 
Head and neck cancers, which affect tissues of the upper aerodigestive tract, 
represent one of the most common and lethal malignancies worldwide. It is estimated 
that in 2016 there will be approximately 61,760 new cases (45,330 men and 16,430 
women) and 13,190 deaths (9,800 men and 3,390 women) in the United States alone1. 
The vast majority (>90%) of head and neck cancer cases are squamous cell 
carcinomas (HNSCC) originating in the epithelial mucosa of various tissues, including 
the oral and nasal cavities, throat (oropharynx, larynx, or hypopharynx), and upper 
digestive tract2, 3. Globally, there are an estimated 550,000 new cases of HNSCC each 
year, and around 300,000 deaths4. The 5-year survival rate is less than 55%, and has 
remained relatively constant for decades, illuminating the dire need for continued 
research into HNSCC chemotherapy and chemoprevention3. My thesis research 
addresses this need; by broadening our understanding of HNSCC at the molecular 
level, I hope to help identify novel targets for more effective strategies for therapy.  
The primary etiological factors of HNSCC are long term and excessive tobacco 
and/or alcohol use, which can act synergistically during carcinogenesis2. Repeated 
exposure of the oral cavity to these carcinogens results in the accumulation of genetic 
mutations and epigenetic changes in cells in the basal and suprabasal layers of the 
epithelium, eventually leading to aberrations in cellular differentiation and 
morphology. Since large areas of tissue are affected by tobacco and/or alcohol 
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exposure simultaneously, tissues exhibit “field cancerization” in which tumor 
development is a multifocal process throughout the exposed region3, 5. Field 
cancerization contributes to a high rate of second primary tumors (SPT) and local 
recurrences among HNSCC patients, complicating treatment and increasing mortality. 
Our lab’s research focuses on tobacco and alcohol-induced carcinomas; however, 
there exists a subgroup of HNSCC cases that is caused by infection with high-risk 
types of human papilloma virus (HPV)2, 3. HPV-positive HNSCC differs genetically 
and molecularly from HPV-negative HNSCC, often occurs in the oropharynx, and 
generally has a more favorable prognosis6.  
Histological and molecular changes observed in HNSCC 
During oral cavity carcinogenesis, striking phenotypic changes occur in the 
stratified squamous epithelium. This tissue is normally a highly-ordered structure 
characterized by multiple layers of cells (keratinocytes) exhibiting distinct patterns of 
differentiation ranging from the inner, basal layer to the outer, cornified layer (Figure 
1.1)7. The basal layer, which adjoins the basement membrane, is highly proliferative 
and contains a basal stem cell population. As these cells undergo terminal 
differentiation, they move upward through the suprabasal and superficial layers before 
eventually dying and being sloughed off. Each layer of keratinocytes represents a 
different state of differentiation and is characterized by the expression of specific 
structural proteins which play a critical role in maintaining the integrity of the 
epithelium8. However, this strict organization is lost during carcinogenesis, as cells of 
the basal and surprabasal layers start exhibiting aberrant differentiation and 
morphology8. Histologically, these changes to the epithelium first manifest as oral 
premalignant lesions (e.g. leukoplakia), before progressing through hyperplasia and 
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dysplasia to become oral squamous cell carcinoma (OSCC) and eventually, metastatic 
cancer9.  
On the molecular level, epithelial cells exhibit changes in many key biological 
pathways including cellular proliferation, cell survival, squamous epithelial 
differentiation, and invasion/metastasis10. Studies of HNSCC have identified genetic 
abnormalities in many well-known tumor suppressor genes and oncogenes, some of 
which will be briefly described here. The tumor suppressive p53 pathway is 
compromised in up to 80% of HNSCC cases, either through inactivating mutations or 
other mechanisms3. In addition, nearly 94% of HNSCCs exhibit alterations in either 
CDKN2A or CCND1, the genes encoding p16 and cyclin D1, respectively11. CDKN2A 
is often inactivated, and CCND1 often amplified or gained, greatly contributing to 
aberrant cellular proliferation and survival3. EGFR overexpression is another common 
characteristic in HNSCC, and is associated with an unfavorable clinical outcome11. 
Figure 1.1: Structure of the stratified squamous epithelium. The stratified 
squamous epithelium, such as that found in the tongue, is composed of multiple layers 
of cells representing different stages of keratinocyte terminal differentiation. The basal 
layer contains a highly proliferative stem cell population that maintains the 
regenerating epithelium. As cells in the basal layer undergo differentiation, they move 
upwards through the suprabasal layers before eventually dying and sloughing off. Left 
panel: adapted from John Wiley & Sons, Inc. Right panel: 7µm paraffin-embedded 
mouse tongue stained with hematoxylin & eosin (200X).
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HNSCC cells also exhibit a characteristic increase in some squamous differentiation 
markers (e.g. involucrin, transglutaminase I, cytokeratin 1 (K1)), as well as decreased 
levels of E-cadherin3, 12. These are just some of the many molecular changes that have 
been identified in HNSCC.  
Current treatment strategies 
While treatment of early-stage primary tumors with radiation and/or surgery is 
often successful, SPT, recurrence, and metastasis necessitate additional treatments, of 
which there are currently few options of only limited clinical efficacy. Currently the 
gold standard for treatment is a combination therapy comprised of a platinum-based 
drug (e.g. cisplatin), fluorouracil (FU) or a taxane, and cetuximab, which is a 
monoclonal antibody that inhibits EGFR13, 14. To date, this regimen has demonstrated 
the greatest clinical activity, and yet still only results in a median survival of 10 
months13. This underscores the dearth of effective chemotherapies available to 
HNSCC patients and the need for novel approaches to treatment and prevention. 
Therefore, my thesis research is focused on a particular signaling pathway that has 
emerged as a compelling target for new therapies in both preclinical and clinical 
studies: the retinoid signaling pathway. 
THE RETINOIC ACID SYNTHESIS AND SIGNALING PATHWAY 
Overview of retinoid signaling 
Vitamin A (retinol) and its natural and synthetic derivatives, retinoids, are 
perhaps some of the most studied and most active agents tested in the treatment and 
prevention of SPT and HNSCC progression15. Endogenous retinoid signaling plays a 
critical role in the regulation of many key cellular events, including embryonic 
development, differentiation, proliferation, and apoptosis16, 17. Retinol is an essential 
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micronutrient obtained from the diet, and cannot be synthesized by vertebrates de 
novo18. Retinol is transported in the blood while complexed to serum retinol-binding 
protein (RBP4), and is taken up by certain types of target cells (such as epidermal 
keratinocytes) via the membrane receptor STRA6 (stimulated by retinoic acid 6) 
(Figure 1.2)19, 20.  
Upon reaching target cells, intracellular retinol has two possible fates. It can 
either be converted to retinyl esters for storage by the enzyme lecithin:retinol acyl 
transferase (LRAT), or it can be metabolized to an active metabolite, the most 
Figure 1.2: Simplified schematic of chief pathways of retinoid signaling and 
metabolism in mammalian cells. Retinol enters the cell via interactions with 
RBP4 and Stra6, whereupon it is converted into a variety of metabolites. It can be 
converted into retinyl esters by LRAT, or into retinaldehyde through the activity of 
RDHs. ALDH1a2, otherwise known as RALDH2, then catalyzes the synthesis of 
RA from retinaldehyde. RA is translocated to the nucleus by binding to CRABP, 
and affects gene expression through its binding and activation of nuclear receptor 
heterodimers. Figure created by Daniel Stummer and adapted from Mongan & 
Gudas, 2007. 
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biologically active of which is all-trans retinoic acid (RA)17. RA synthesis from retinol 
occurs through a series of two enzymatic steps. First, all-trans retinol is reversibly 
oxidized by alcohol dehydrogenases (ADHs) or retinol dehydrogenases (RDHs) to 
form all-trans retinaldehyde. Aldehyde dehydrogenases (ALDHs) then irreversibly 
oxidize all-trans retinaldehyde to form RA21. Free cytoplasmic RA can then be 
translocated to the nucleus by cellular retinoic acid binding protein 2 (CRABP2), 
whereupon RA exerts its biological effect by binding to and activating specific nuclear 
receptors – retinoic acid receptors (RARs) and retinoid X receptors (RXRs)22. These 
receptors function as RAR/RXR heterodimers, and are bound to specific DNA 
sequences known as retinoic acid response elements (RAREs) in order to control the 
transcription of a wide assortment of downstream genes (Figure 1.2)23. Activation of 
RAR/RXR by a retinoid agonist causes the dissociation of co-repressors and 
recruitment of co-activators, inducing transcription24. In addition, RXRs can dimerize 
with other nuclear receptors, such as the peroxisome proliferator-activated receptor 
(PPARβ/δ), to initiate transcriptional changes and cellular responses distinct from 
those initiated by RAR/RXR25, 26.  
Besides acting as classical transcription factors, retinoid receptors can also 
affect gene expression by inducing epigenetic changes that modify the chromatin 
structure27, 28. For example, our lab has demonstrated that in the presence of a retinoid 
agonist, RAR-regulated genes acquire H3K4/9ac activation marks and lose 
H3K27me3 marks, stimulating transcriptional activation29-31. Such epigenetic changes 
occur as a result of the action of numerous co-regulators associated with the retinoid 
receptors, and these modifications can be long-term and stable32. Co-repressors inhibit 
transcriptional activation by retinoid receptors until an agonist is present, at which 
point they disassociate to allow for binding of co-activators. Known co-repressors 
include the nuclear receptor co-repressor (NCoR) and the silencing mediator of 
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retinoic acid and thyroid hormone receptor (SMRT), which mediate the recruitment of 
repressor complexes that contain histone deacetylases (HDACs)33. Research in our lab 
has shown that the polycomb repressive complex (PRC2), an epigenetic silencing 
complex that contains histone methyltransferase (HMT) activity and is responsible for 
H3K27me3, is also displaced from RAREs by RA signaling29, 34, 35. Notable co-
activators include proteins with histone acetyltransferase activity, e.g. p300/CBP, 
pCAF, and p160 co-activators17. Thus, retinoids are potent signaling biomolecules that 
can have pleiotropic effects by modulating the transcription and epigenetic status of 
many important and diverse genes16-18.  
Retinoid signaling is disrupted in cancer 
Aberrations in retinoid signaling and metabolism are frequently observed in 
human epithelial cancers, including HNSCC17. Prostate, skin, colon, kidney, and 
breast cancers also often exhibit alterations in this pathway25, 36-39. Since one of the 
physiological functions of retinoid signaling is to maintain normal cell growth and 
differentiation, it follows that aberrations in this pathway would disrupt this regulation 
and promote the malignant cellular dysregulation observed in HNSCC. Changes in 
this pathway that have been observed in HNSCC include reductions in LRAT, RARγ, 
RARβ2, and CRABP2 mRNA and protein levels, as well as increases in cytochrome 
P450 26A1 (CYP26A1), which is the enzyme that catalyzes the first step of RA 
degradation (Figure 1.2)6, 17, 40-45. In the case of RARβ2, expression is lost via 
hypermethylation of the promoter (rather than genetic mutation), and is believed to be 
an early event in carcinogenesis46, 47. In addition, early studies (first reported in 1925 
by Wolbach and Howe) found that vitamin A deficiency induces squamous metaplasia 
in the mucosa of the upper aerodigestive tract, similar to premalignant events in the 
mucosa of heavy smokers46, 48. Conversely, epidemiologic studies found that a high 
8 
 
dietary intake of vitamin A is associated with slower progression of carcinogenesis of 
several cancers, including OSCC49. This inverse association between cancer 
development and retinoid status and signaling illustrates the importance of the 
endogenous retinoid pathway in maintaining proper endogenous differentiation and 
preventing malignant transformation.  
Retinoid use in cancer treatment and prevention 
Restoration of retinoid signaling is therefore an attractive therapeutic strategy 
to reinstate the normal pathway of differentiation and inhibit the malignant phenotype. 
Clinically, retinoids have been a chemotherapeutic and chemopreventative focus for 
decades and are already used in a number of successful treatment regimens for various 
malignancies17, 25, 50. Most notably, acute promyelocytic leukemia (APL), which used 
to have a high mortality rate, is now the most curable subtype of acute myelocytic 
leukemia51, 52. This is due to the addition of RA treatment to the standard 
anthracycline-based chemotherapy, which increased the long-term survival from just 
40% to above 80%51, 52. Recently, a phase III clinical trial was able to increase this 
survival rate even further; the combination of RA and arsenic trioxide demonstrated a 
two-year event-free survival rate of 97% (versus 86% seen with RA and 
chemotherapy)53. This application exemplifies the use of retinoids as differentiation 
therapy, as treatment with RA causes abnormal promyelocytic leukemia cells to 
differentiate into normal granulocytes, preventing further proliferation25, 54.  
In the context of squamous cell carcinoma, modulating retinoid signaling has 
yielded promising results in cell culture and xenograft studies. Transfection of RARβ 
into the human esophageal squamous cell carcinoma line TE-8, which does not 
express RARβ, induced apoptosis and inhibited proliferation and colony formation47, 
55. This induction of RARβ also suppressed the expression of cyclooxygenase (COX)-
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2, an enzyme that shows increased expression in HNSCC and has been linked to 
carcinogenesis and metastasis. In addition, a skin cancer study showed that loss of 
RARγ predisposed epidermal keratinocytes to Ras-induced squamous cell carcinoma 
in vivo in xenograft experiments, suggesting that RARγ acts as a tumor suppressor in 
this cell type56. Both of these studies link loss of retinoid signaling to epithelial 
tumorigenesis. 
Furthermore, a large body of work has explored the effectiveness of treatment 
with exogenous retinoids, either alone or in combination, in HNSCC. Treatment of 
many different human HNSCC cell lines with RA inhibits cell proliferation and 
decreases mRNA and protein levels of squamous differentiation markers that are 
aberrantly overexpressed in HNSCC: transglutaminase type 1, involucrin, and K112, 57. 
In contrast, culturing the HNSCC cell line 1483 in delipidized serum, from which 
endogenous retinoids have been extracted, increased the expression of these same 
three differentiation markers58. Recent work has found evidence that RA treatment 
inhibits the growth of HNSCC cancer stem cells (CSCs) by inducing differentiation 
and suppressing Wnt/β-catenin signaling59. RA given alone or in combination with 
sodium butyrate was found to inhibit cell growth and to induce cell cycle G1 arrest 
and its associated markers (cyclin-dependent kinase 6, p21, and p27) in human OSCC 
cell lines SCC-1 and SCC-960. In the human tongue SCC line Tca8113, treatment with 
RA and antisense oligonucleotides against hTR had a synergistic anti-tumor effect, 
inducing apoptosis in vitro and inhibiting tumor growth in xenograft experiments61. 
Interestingly, retinoid administration also enhances the cytotoxic effects of cisplatin in 
cell culture and xenograft experiments62.  
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Retinoid use in a murine model of OSCC 
Studies conducted in our lab using a carcinogen-induced murine model of 
OSCC have further elucidated an anti-tumorigenic role for retinoids and retinoid 
signaling. In this mouse model, which was first developed in our lab by Tang et al., 
mice are administered the carcinogen 4-nitroquinoline 1-oxide (4-NQO) in the 
drinking water63. Similar to tobacco and its related carcinogens, 4-NQO causes DNA 
adduct formation, resulting in adenosine substitution for guanosine63, 64. 4-NQO-
treated mice develop carcinomas that resemble human HNSCC morphologically, 
histologically, and molecularly, making this an excellent animal model for 
experimentation63. Our lab found that treatment with RA in combination with 5-Aza-
2’-deoxycytidine (5-Aza), a DNA methyltransferase inhibitor, reduced oral cavity 
carcinogenesis and increased RARβ2 mRNA levels in 4-NQO treated mice (relative to 
mice treated with 4-NQO + PBS)65. Researchers in our lab also reported that treatment 
with bexarotene (a RXR agonist) and CD1530 (a RARγ agonist) reduced oral cavity 
carcinogenesis in this mouse model66. Lastly, in a model of 4-NQO-induced 
carcinogenesis in rats, Choi et al. found that a single injection of RA-loaded 
microspheres was able to suppress oral carcinogenesis67. Together, these animal 
studies reveal that retinoid treatment can inhibit oral carcinogenesis in mice in vivo.  
Retinoid-based therapies: clinical trials 
The early clinical successes of retinoid treatment in suppressing epithelial 
carcinogenesis helped to define the modern concept of clinical cancer 
chemoprevention68. In HNSCC, much of the focus has been on the use of 13-cis-RA 
(13-cRA, also known as isotretinoin), a naturally occurring isomer of RA that has 
more favorable pharmacokinetic properties15. In initial clinical trials, high-dose 13-
cRA was efficacious in suppressing oral premalignant lesions (leukoplakia) and SPT 
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in HNSCC patients69, 70. Furthermore, researchers reported that treatment with 13-cRA 
restored RARβ mRNA expression, and that restoration of RARβ mRNA was 
associated with clinical response71. However, in a subsequent large-scale randomized 
phase III clinical trial, low-dose 13-cRA given orally as a single drug was not effective 
in preventing SPT or recurrence in early-stage HNSCC patients72. This result was 
likely affected by the inclusion of “current smokers” in this and related trials; it has 
been reported that when compared to “former” and “never” smokers, current smokers 
have a statistically significantly higher rate of SPT and mortality68, 72. In addition, this 
randomized phase III trial tested a much lower dose of 13-cRA than previous trials (30 
mg/day vs. 50-100 mg/m2/day), prioritizing patient tolerance over chemopreventative 
efficacy70. 
These limited but promising clinical results have prompted further study into 
the pharmacology of retinoids in HSNCC and investigation into novel retinoid therapy 
options. Combination therapy is one attractive option that is currently being explored. 
Treatment of advanced HNSCC patients with a combination of 13-cRA, interferon-
α2a, and chemotherapy has yielded promising results and is awaiting further 
confirmation by randomized studies52. Another research interest is the additional 
characterization of the proteins involved in the endogenous retinoid signaling pathway 
and their roles in potentially preventing HNSCC. Such studies could yield new 
insights and inspire new and more effective strategies for therapy to complement or 
improve upon existing treatments with exogenous retinoids.  
ALDH1A2: A PUTATIVE TUMOR SUPPRESSOR 
One enzyme in the endogenous retinoid synthesis and signaling pathway that is 
currently of interest in the field is ALDH1a2, or aldehyde dehydrogenase family 1 
member A2 (previously known as RALDH2; Gene ID: 8854). ALDH1a2 is a 
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cytosolic, NAD-dependent enzyme that catalyzes the final step of RA synthesis: the 
irreversible oxidation of all-trans-retinaldehyde to yield RA (Figure 1.2)21, 73. The 
cloning of mouse, human, and chick ALDH1a2 homologs revealed 94-98% amino 
acid sequence similarity, indicating that ALDH1a2 is highly evolutionarily 
conserved74.  Much of the research on ALDH1a2 to date has been in the context of 
normal prenatal development, as an ALDH1a2 gene knockout is embryonic lethal in 
developing mice due to defects in heart morphogenesis75, 76. This reflects the 
importance of embryonic RA synthesis from retinol. Research on zebrafish has also 
identified an intriguing role for ALDH1a2 in tissue regeneration; ALDH1a2 
transcripts are highly induced after amputation of the adult fin, larval fin, and heart, 
and inhibition of ALDH1a2 using a small molecule inhibitor or morpholino prevented 
organ regeneration27, 77.  
In cancer studies, ALDH1a2 has emerged as a candidate tumor suppressor. The 
first work suggesting this was conducted by Kim et al., in which they found that the 
ALDH1a2 promoter is hypermethylated in the majority of human prostate tumors, and 
that ALDH1a2 is expressed in normal but not tumor prostate epithelium (Figure 
1.3A)78. Restoration of ALDH1a2 expression, either through transfection with 
exogenous ALDH1a2 or treatment with 5-Aza, suppressed colony formation of human 
prostate cancer cell lines (Figure 1.3C,D)78. In addition, mouse studies in our lab 
revealed that ALDH1a2 protein levels were significantly lower in prostate tissue in a 
transgenic mouse model of prostate cancer as compared to control mice79. Loss of 
ALDH1a2 expression has also been reported in human ovarian cancer cells, 
contributing to an overall reduction in retinol metabolism80. Additionally, high 
ALDH1a2 mRNA levels correlate with better overall survival for breast cancer 
patients81.  
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Research on ALDH1a2 in the context of HNSCC is more recent. Because 
HNSCC patients with HPV-driven tumors show a favorable prognosis compared to 
patients with non-HPV-driven tumors, researchers used an array-based approach to 
identify differences in promoter methylation that might contribute to this difference in 
clinical response. In 2013 they reported that hypermethylation of the ALDH1a2 
promoter was a common feature of tumors from patients with non-HPV-driven 
HNSCC and that there was a strong correlation between ALDH1a2 protein levels and 
a favorable clinical outcome, independent of HPV status (Figure 1.4)6. The same 
group further extended these observations using cell culture and xenograft-based 
Figure 1.3: ALDH1a2 is expressed in normal, but not tumor, prostate 
epithelium, and its reexpression inhibits colony formation in prostate cancer 
cells in vitro (adapted from Kim et al., 2005). (A,B) ALDH1a2 immunostaining of 
a tissue microarray comprised of n=21 primary prostate tumors and matched normal 
prostate specimens. Images were taken at 100X (left panels) and 400X (right panels). 
(A) Representative images from a normal prostate epithelium and (B) matched 
prostate tumor from the same individual. (C) Western blot analysis verifying 
ALDH1a2 overexpression in prostate cancer cell line DU145 24-hours after 
transfection . α–tubulin was used as a loading control. (D) Representative colony 
formation assay of empty-vector- and ALDH1a2-transfected DU145 cells. 
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studies. They treated the human HNSCC cell lines FaDu and Detroit562 with 
WIN18.446, a bisdichloroacetyldiamine that is a known inhibitor of ALDH1a2, and 
with BMS493, an inverse agonist of pan-RAR which enhances NCoR interaction with 
RARs82, 83. They observed that treatment of these cells with WIN18.446 or BMS493 
resulted in a loss of cell-to-cell junctions and the formation of more poorly-defined 
clusters, indicative of a loss of epithelial morphology. In addition, they detected a 
significant increase in the transcript levels of the mesenchymal markers vimentin and 
N-Cadherin in FaDu cells following treatment with either inhibitor. These results 
suggest that the inhibition of ALDH1a2-RAR signaling in HNSCC cells results in a 
loss of cell adhesion and a gain of a mesenchymal-like phenotype. Moreover, in a 
mouse xenograft model they found that silencing ALDH1a2 using shRNA accelerated 
tumor growth in vivo and resulted in increased tumor vimentin expression, again 
reflecting a more mesenchymal tumor phenotype (Figure 1.5)82. These studies 
confirmed a link between ALDH1a2 signaling (or lack thereof) and the pathogenesis 
of HNSCC, however this relationship is still poorly defined. 
In the research described herein, we investigated the role of ALDH1a2 in 
HNSCC tumorigenesis. First we explored the effects of ALDH1a2 expression in 
transformed human SCC cell lines to delineate the effects of ALDH1a2 on the 
preexisting malignant phenotype. We then generated a novel transgenic mouse line 
that showed inducible and tissue-specific expression of ALDH1a2 to determine 
whether or not ALDH1a2 induction could attenuate the development or progression of 
oral cavity carcinogenesis in the 4-NQO mouse model. In total, we explored the 
therapeutic and preventative potential of the enzyme ALDH1a2 in HNSCC. 
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Figure 1.4: ALDH1a2 protein expression correlates with better clinical outcome 
of HNSCC patients (adapted from Kostareli, et al., 2013). (A) Immunostaining of 
tissue microarrays generated from primary tumors of n=115 HNSCC patients with 
known HPV status (n=89 non-HPV-driven; n=29 HPV-driven). They observed low-
to-moderate staining for ALDH1a2 protein in keratinocytes in the healthy oral 
mucosa as well as in n=73 (63.5%) primary tumors (“ALDH1a2low”).  High 
ALDH1a2 protein levels were detected in n=42 (36.5%) primary tumors 
(“ALDH1a2high). Tissues were counterstained with hematoxylin (blue nuclear stain). 
Scale bar represents 100µm). (B) Higher ALDH1a2 protein expression was detected 
in HPV-driven tumors compared to non-HPV-driven. Bars denote medians. Data 
was analyzed using a 2-tailed Mann-Whitney U test. (C) Kaplan-Meier plot for 
overall survival (OS) with respect to ALDH1a2 protein level in n=115 HNSCC 
patients. A log-rank/Mantel-Cox test was used to determine p values. 
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Figure 1.5: Silencing ALDH1a2 accelerated tumor growth and increased tumor 
vimentin expression in a mouse xenograft model (adapted from Seidensaal, et 
al., 2015). (A) Western blot analysis demonstrating shRNA-mediated silencing of 
ALDH1a2 expression in human SCC cell line, FaDu. FaDu-mock cells were used as 
a negative control. (B) Representative images of IHC staining of tumor sections 
from FaDu-mock or FaDu-shALDH1a2-injected xenografts to analyze ALDH1a2 
and vimentin expression. Increased vimentin expression was observed in FaDu-
shALDH1a2 tumors. (C) Quantfication of tumor volume (in mm3) in mice (n=4 per 
group) at various times following implantation with FaDu-mock or FaDu-
shALDH12 cells. Tumor growth was homogeneous among FaDu-shALDH1a2-
implanted mice, however 50% of FaDu-mock tumors exhibited slower growth. (D) 
Inverse expression of ALDH1a2 and vimentin expression was observed in primary 
tumors via IHC of serial tumor sections. 
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CHAPTER TWO 
ALDEHYDE DEHYDROGENASE 1A2 IS REDUCED IN HEAD AND NECK 
SQUAMOUS CELL CARCINOMA AND IS A PUTATIVE TUMOR 
SUPPRESSOR 
 
INTRODUCTION  
 Head and neck cancer, which includes cancers of the upper aerodigestive tract, 
represents one of the ten most common cancers worldwide and is characterized by high 
rates of morbidity and mortality1. In addition, outside of radiation and surgery, there are 
currently few therapeutic options of limited clinical efficacy available1. The vast 
majority of cases (~90%) are squamous cell carcinomas (HNSCCs), of which one of the 
primary etiological factors is long-term and excessive tobacco and/or alcohol use2, 3. 
Repeated exposure to these carcinogens results in multifocal lesion development in the 
epithelium of exposed tissues, such as the oral cavity and esophagus4. One of the current 
challenges in HNSCC research is to identify new drug targets and treatment strategies 
for more effective and less toxic therapies. 
 One pathway that has emerged as a potential target for 
chemotherapy/chemoprevention is the retinoid signaling pathway, which plays a critical 
role in regulating cellular differentiation, proliferation, and apoptosis5. Retinoids 
include vitamin A (retinol) and its natural and synthetic derivatives. In the endogenous 
signaling pathway retinol enters the cell and is converted into its most biologically-
active metabolite, all-trans retinoic acid (RA), through a series of enzymatic steps 
occurring in the cytoplasm (Figure 1.2)6. A key step is catalyzed by aldehyde 
dehydrogenase 1a2 (ALDH1a2), which irreversibly oxidizes all-trans retinaldehyde to 
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synthesize RA7. RA is then shuttled to the nucleus by intracellular lipid binding proteins, 
whereupon it binds to and activates specific nuclear receptors – retinoic acid receptors 
(RARs) – to regulate the transcription of many diverse target genes5.  
 Retinoid signaling is required for the normal growth, differentiation, and 
function of epithelial cells8. Thus, aberrations in retinoid signaling and metabolism 
contribute significantly to malignant dysregulation and are frequently observed in 
HNSCC and other cancers9, 10. Restoration of retinoid signaling through treatment with 
exogenous retinoids has exhibited efficacy in both preclinical and clinical trials11. 
Numerous studies have reported that retinoid treatment modulates cellular 
differentiation and inhibits proliferation of cultured human HNSCC cell lines11-14. 
 The enzyme ALDH1a2 has recently emerged as a candidate tumor suppressor 
in several epithelial cancers15-18. Of note, researchers found that ALDH1a2 is expressed 
in normal but not cancerous prostate epithelium, and that its re-expression via 
transfection with exogenous ALDH1a2 inhibited the colony formation of prostate 
cancer cell lines17. Furthermore, decreased ALDH1a2 expression induced a 
mesenchymal-like phenotype and accelerated tumor growth in a xenograft model of 
HNSCC in vivo18. These results suggest an inverse correlation between ALDH1a2 
expression and tumorigenesis in select cancers. 
 In the current study we investigated whether ALDH1a2 expression is reduced in 
HNSCC, and hypothesized that reinstatement of ALDH1a2 expression inhibits HNSCC 
cell growth by increasing cellular retinoic acid signaling. To address this question we 
used a viral vector to drive overexpression of ALDH1a2 in human HNSCC cell lines 
and assessed the resulting phenotype.  Overall, our results provide evidence that 
ALDH1a2 functions as a tumor suppressor in HNSCC. 
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MATERIALS AND METHODS  
Analysis of ALDH1a2 mRNA expression in human HNSCC patients 
 I analyzed ALDH1a2 mRNA levels in human HNSCC patients compared to 
matched normal tissue using Oncomine, a publicly available cancer microarray database 
(www.oncomine.org; Compendia Biocience)19. I examined transcript expression in ten 
available human HNSCC datasets from eight separate studies, some of which analyzed 
a specific tissue. All datasets utilized are detailed in Results Figure 2.1. We excluded 
datasets from pharyngeal tissue, as our interest lies in carcinomas of the oral cavity 
(OSCC). 
Cell Culture 
 All cell lines used in this study were maintained as previously described8, 20. 
Briefly, the immortalized, non-transformed human oral keratinocyte cell line OKF4-
TERT1 (OKF4) was generously provided by Dr. James G. Rheinwald, Harvard Medical 
School, and was cultured in Keratinocyte-SFM (Cat. No. 10744019; Gibco) 
supplemented with ~12 µg/mL bovine pituitary extract (BPE) (Cat. No. 13028-014; 
Gibco), penicillin (10,000 U/mL)/streptomycin (10,000 U/mL) (Cat. No. 10378-016; 
Gibco), 0.3 mM CaCl2, and 0.2 ng/mL epidermal growth factor (EGF) (Cat. No. 10450-
013; Gibco)20. Transformed human OSCC cell lines SCC-4, SCC-9, and SCC-25 were 
grown in Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-
12) (Cat. No. 11320-033; Gibco) supplemented with 10% fetal bovine serum (FBS) and 
400 ng/mL hydrocortisone21. All three SCC cell lines were generated by Dr. Rheinwald 
and obtained from the ATCC (Cat. No. CRL-1624, CRL-1629, and CRL-1628, 
respectively). HEK293T cells (ATCC) were cultured in DMEM (Gibco) supplemented 
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with 10% FBS. Each cell line was grown in a humidified atmosphere of 5% CO2 at 
37°C, and media was changed every 3 days.  
Overexpression of ALDH1a2 by retroviral infection 
 To generate the retroviral vector driving constitutive ALDH1a2 overexpression, 
I inserted the AgeI fragment of pCMV-Sport6/ALDH1a2 (containing the ALDH1a2 
cDNA) into the AgeI site of the retroviral vector pQCXIP (Cat. No. 631516; Clontech 
Laboratories, Inc.). This generated pQC-ALDH1a2 (Supplemental Figure 2.1). 
Retroviral stocks were produced by transfecting HEK293T cells with pQC (empty 
vector control) or pQC-ALDH1a2 and collecting viral supernatant at 48 hours post-
transfection, as described previously22, 23. Parental keratinocytes were transduced with 
viral supernatant in a 1:4 ratio with growth medium (DMEM + 10% FBS) overnight 
(12-16 hours). At this point, I replaced the media with normal growth medium with 0.5 
µg/mL puromycin (Sigma) for selection, and changed it every 2-3 days for a total of 7-
10 days, before harvesting or plating the cells for experiments.  
RNA isolation and RT-PCR analysis 
Total RNA was extracted using TRIzol reagent and isolated according to the 
manufacturer’s protocol (Cat. No. 15596; Invitrogen). Total mRNA (1 µg) was reverse 
transcribed using qScript cDNA Supermix (Cat. No. 95048; Quanta Biosciences, Inc.) 
and diluted 1:10 with dH2O24. Resulting cDNA (2 µL) was used as a template for 
semiquantitative RT-PCR using a Bio-Rad iCycler as previously described25. I utilized 
primers specific for housekeeping gene hypoxanthine phosphoribosyltransferase 1 
(HPRT1) as a loading control, as previously described8, 26. Primer sequences are listed 
in Table 2.1.  
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Table 2.1: Primer sequences used for RT-PCR 
Gene Forward Primer  (5'-3') 
Reverse Primer  
(5'-3') 
Product 
Size 
ALDH1a2 TG gacttgtagcagctgtcttcact tcacccatttctctcccatttcc 160 bp 
HPRT1 tgaggatttggaaagggtgt aatccagcaggtcagcaaag 155 bp 
 
Protein isolation and western blot analysis 
 Total protein from cultured cells was extracted in final sample buffer (0.5 M 
Tris–HCl, pH 6.8, 10% glycerol and 1% SDS), sonicated, boiled, and quantified using 
the DC Protein Assay (Cat. No. 500-0112; Bio-Rad). I separated 10 µg total protein on 
SDS-PAGE gels and transferred protein onto nitrocellulose membranes as previously 
described. Membranes were blocked in 5% skim milk in Tris-buffered saline containing 
0.1% TWEEN 20 (Cat. No. P1379; Bio-Rad) (TBST) for 1 hour at room temperature 
before incubation with primary antibodies diluted in blocking solution, overnight at 4°C. 
Following two washes with TBST, membranes were then incubated with appropriate 
secondary antibodies for 1 hour at room temperature, washed with TBST, and developed 
using the Pierce ECL Substrate Kit (Cat. No. 32106; Pierce). I used a quantitative gel 
imaging station (Bio-Rad ChemiDoc System) and ImageLab software to record and 
analyze membrane chemiluminescence. Primary antibody details are provided in Table 
2.2.  
 
Table 2.2: Primary antibodies 
PC = polyclonal antibody; MC = monoclonal antibody 
ǂ A custom anti-ALDH1a2 antibody was generated for our lab by Alpha Diagnostics 
Target  Company Catalog # Lot # Source Dilution 
ALDH1a2 Alpha Diagnostics  N/A ǂ Batch #4 Rabbit PC 1:100 
-Actin Millipore MAB1501 2665057 Mouse MC 1:80,000 
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Immunofluorescence staining 
 I performed immunofluorescence staining as previously described27. Briefly, 
cells were grown in monolayer on glass coverslips that had been pre-treated with FBS. 
Cells were then fixed with 4% (w/v) paraformaldehyde for 1 hour at room temperature, 
after which they were permeabilized using 0.3% (w/v) Triton X-100 for 3 minutes at 
room temperature. I then blocked with 2% BSA (in PBS) for 30 minutes before probing 
with primary antibody (Table 2.2) overnight at 4°C. Alexa Fluor 488 fluorescent 
secondary antibody (Invitrogen; 1:300) was used to probe for the protein of interest and 
Phalloidin-TRITC (Cat. No. FAK100; Millipore; 1:1000) was utilized for actin 
cytoskeleton counterstaining; both were applied for 1 hour at room temperature, with 
the plate wrapped in foil to prevent quenching of the fluorescent signal. Cell coverslips 
were mounted on slides using Vectashield mounting medium containing DAPI (Cat. 
No. H-1200; Vector Labs) to stain for cell nuclei. I imaged the slides using a Nikon 
TE2000-E microscope and CoolSnap HQ2 camera (Roper Scientific). 
Proliferation and colony formation assays 
 For proliferation assays, I plated cells in triplicate at a density of 10,000 
cells/well in a 12-well plate at day -1. Cell numbers were counted at days 0, 3, 5 and 7, 
using a cell and particle counter (Coulter Z1, Beckman Coulter, Inc.). For colony 
formation assays, cells were plated at a density of 500 cells/well in a 6-well plate, and 
allowed to grow for approximately 14 days. Cells were then rinsed with PBS before 
fixation and staining using a mixture of paraformaldehyde (4%) and crystal violet (0.5% 
w/v) in PBS for 30 minutes at room temperature28. Crystal violet dye binds to proteins 
and DNA and is an effective means of visualizing viable adherent cells28. Cells were 
treated with 1 µM RA in DMSO (or vehicle control), starting at day 0. Throughout both 
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assays, growth medium was changed every 2 days. ImageJ Software (National Institutes 
of Health) was used to quantify the number and size of colonies.  
Statistical analysis 
 All experiments include at least 3 independent biological replicates (n≥3). 
Statistical analyses were conducted using GraphPad Prism 6.0 software. The means ± 
S.E.M. were calculated before applying the Student’s unpaired t test, or a one- or two-
way ANOVA, as indicated in the figure legends. Differences of p < 0.05 were 
considered statistically significant.  
RESULTS 
ALDH1a2 expression is decreased in HNSCC 
 We first wanted to ascertain whether ALDH1a2 is aberrantly expressed in 
human OSCC. Using the online database Oncomine, we identified eight different 
studies of published microarray data from human OSCC patients29-36. In total, these 
studies include ten data sets which compared gene expression data from 229 carcinoma 
samples and 135 adjacent, non-tumor samples. We found that in the majority of the 
available data sets (70%, 7/10 data sets), ALDH1a2 was in the top 25% of genes with 
reduced transcript levels in cancer versus normal tissue (Figure 2.1). Strikingly, in four 
of these studies, ALDH1a2 was in the top 1-5% of underexpressed genes. This analysis 
reveals that ALDH1a2 mRNA levels are greatly reduced in human OSCC compared to 
normal oral tissue. 
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 We next examined ALDH1a2 protein levels in three transformed tongue SCC 
cell lines – SCC-4, SCC-9, and SCC-25 – and one normal, immortalized oral mucosal 
keratinocyte line, OKF4. Western blot analysis revealed that ALDH1a2 protein levels 
are decreased in all three SCC lines as compared to OKF4 (Figure 2.2). ALDH1a2 
Figure 2.1: Summary of ALDH1a2 underexpression as observed in eight studies 
that collected microarray data from OSCC samples and adjacent healthy tissue. 
We examined every OSCC patient microarray data set available on Oncomine.com; 
this amounted to 10 data sets collected in 8 different studies. Together, these data sets 
represent 229 carcinoma samples and 135 adjacent, non-tumor samples from human 
patients. Shades of blue, as observed in 7 of 10 data sets, indicate ALDH1a2 is in the 
top 25% of underexpressed genes. Medium-dark blue, as seen in 4 of the data sets, 
means ALDH1a2 is in the top 1-5% of underexpressed genes. Gene overexpression, 
which would be represented by shades of red, was not observed in any of the data sets. 
OncomineTM July 8, 2016. 
1 % 5% 10% 25% 
Underexpression: Gene Rank 
>25% 
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protein levels are reduced by approximately 86.4% (±6.6%; p=0.0002), 84.4% (±8.2%; 
p=0.0002) and 76.1% (±11.8%; p=0.004) in SCC-4, SCC-9, and SCC-25 cell lines, 
respectively, compared to the non-transformed OKF4 cells (Figure 2.2D). Together, 
these results from the patient microarray data and human SCC cell lines indicate that 
ALDH1a2 mRNA and protein levels are generally decreased in human OSCC.  
 
 
 
 
 
Figure 2.2: Endogenous ALDH1a2 expression is decreased in HNSCC cell lines. 
(A) Western blot analysis of OKF4, SCC-4, SCC-9, and SCC-25 keratinocyte lines. 
Membranes were probed with 1:100 ALDH1a2 antibody and 1:10,000 β-actin (loading 
control). Image shown is representative of analyses performed on distinct biological 
samples (n=3) with similar results. (B) Quantification of n=3 western blots such as 
shown in panel (A) using ImageLab Software (Bio-Rad). ALDH1a2 protein levels are 
normalized to β-actin protein levels and are represented relative to protein levels in 
OKF4 cells (set as 1). Bars represent mean± S.E.M. and data were analyzed using One-
way ANOVA; ⁎⁎⁎ indicates p<0.001. 
A B 
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ALDH1a2 overexpression suppresses proliferation and colony formation of SCC cells 
 To determine the functional role of ALDH1a2 in neoplastically transformed oral 
keratinocytes we generated a viral construct to drive the constitutive overexpression of 
ALDH1a2 (pQC-ALDH1a2; Supplemental Figure 2.1), and infected human squamous 
cell carcinoma cell lines SCC-4, SCC-9 and SCC-25. We used RT-PCR to confirm 
overexpression of transgenic (TG) ALDH1a2 mRNA in all three SCC lines (Figure 
2.3A). No TG ALDH1a2 transcript was detected in cells infected with an empty control 
vector (pQC). Using immunofluorescence to detect total (endogenous + TG) ALDH1a2 
protein, we verified that ALDH1a2 is overexpressed at the protein level in each pQC-
ALDH1a2-infected SCC line (Figure 2.3B). 
 We then conducted phenotypic assays to determine the effect of ectopic 
ALDH1a2 expression on SCC cell growth. All three SCC cell lines infected with pQC-
ALDH1a2 exhibited reduced proliferation over 7 days compared to empty vector-
infected cells (Figure 2.4A-C). We also treated empty vector-infected cell lines with 
exogenous RA (1 µM). Since endogenous ALDH1a2 synthesizes intracellular RA, 
treatment with exogenous RA serves as a positive control for increased RA signaling. 
ALDH1a2 overexpression reduced SCC-4 and SCC-9 cell number by more than 40% 
(44% p≤0.0001, and 43% p=0.0002, respectively) and SCC-25 cell number by 23% 
(p=0.0014) (Figure 2.4A,B). In addition, RA treatment reduced the number of SCC-4, 
SCC-9, and SCC-25 cells by 26% (p=0.0016), 23% (p=0.0092), and 32% (p=0.0002), 
respectively.  
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Figure 2.3: ALDH1a2 overexpression in human HNSCC cell lines. We infected 
SCC-4, SCC-9, and SCC-25 cells with either empty pQC vector (+EV) or a vector 
driving constitutive expression of ALDH1a2 (pQC-ALDH1a2; +ALDH1a2; 
Supplemental Figure 2.1) and selected 7-10 days with puromycin before harvesting the 
cells for analysis. (A) RT-PCR analysis of infected cell lines. One cohort of each EV-
infected cell line was treated with 1 µM RA for 7 days as a positive control for the 
phenotypic assays shown in Figures 2.4 and 2.5 (+EV +RA). We used primers specific 
for the transgenic (TG) ALDH1a2 transcript as described in Table 2.1. HPRT1 was used 
as a loading control. (B) Immunofluorescence visualization of ALDH1a2 protein in EV- 
and ALDH1a2-infected cells. Cells were probed with ALDH1a2 primary antibody 
(Table 2.2) (green, 1:100) and stained with DAPI (blue, nuclei) and Phalloidin-TRITC 
(red, actin cytoskeleton). Images shown are representative of analysis performed on 
independent experiments (n=3) with similar results, and were taken at 200X. Scale bar 
represents 50 µm. 
B 
A 
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Figure 2.4: ALDH1a2 overexpression impairs proliferation in HNSCC cell lines. 
We infected SCC-4 (A), SCC-9 (B), and SCC-25 (C) cells overnight with empty 
vector (+EV) or a vector driving constitutive expression of ALDH1a2 (+ALDH1a2, 
Supplemental Figure 2.1) and selected 7-10 days with puromycin before plating for 
experiments. All cells were seeded at 10,000 cells/well, and allowed to attach for 24 
hours before treatment and counting at Day 0. We treated one cohort of EV-infected 
cells with 1 µM RA. The remaining lines were treated with an equivalent volume of 
vehicle control (DMSO). Cells were counted on days 2, 5, and 7, and raw cell numbers 
were normalized to the cell count of the Day 7 EV-infected line (set as 1). We plated 
each independent experiment in triplicate. Each data point represents the mean of n≥3 
separate experiments (biological repeats) ±SEM. The data was analyzed using two-
way ANOVA; ⁎ indicates p<0.05, ⁎⁎ indicates p<0.01, ⁎⁎⁎ indicates p<0.001 and 
⁎⁎⁎⁎ indicates p<0.0001. 
B 
C 
A 
38 
 
 To further verify the inhibitory effect of ALDH1a2 on SCC cell growth, we 
overexpressed ALDH1a2 in SCC cells and assayed for colony formation. When seeded 
at low density, ALDH1a2-infected SCC-4 and SCC-9 cells showed reduced colony-
forming ability compared to cells infected with the empty vector control in terms of 
average colony size and number of colonies (Figure 2.5A,B). Colony number and size 
reflect cell survival and proliferation, respectively37. ALDH1a2 overexpression did not 
significantly affect the clonogenicity of SCC-25 cells (Figure 2.5A,B, bottom row). 
Treatment with exogenous RA inhibited colony formation in SCC-9 cells, but not SCC-
4 or SCC-25. Consistent with our cell proliferation assays, these data confirm that 
ALDH1a2 expression suppresses SCC growth in vitro.  
 We also infected OKF4 cells with the pQC and pQC-ALDH1a2 viral vectors in 
order to determine the effect of ectopic ALDH1a2 on the growth of non-transformed 
keratinocytes. We observed no change in proliferation or colony formation in 
ALDH1a2-infected OKF4 cells as compared to empty vector-infected cells 
(Supplemental Figure 2.2B,C). In contrast, treatment with exogenous RA (1 µM) 
decreased cell number by 83% (p<0.0001) at Day 7 of our proliferation assays and 
prevented in vitro colony formation (Supplemental Figure 2.2B,C). These results 
suggest that ALDH1a2 overexpression does not significantly affect the growth of the 
non-transformed keratinocyte line OKF4. 
DISCUSSION 
 The retinoid signaling pathway has been of interest in the context of HNSCC for 
some time; retinoids suppress the proliferation of HNSCC cells in culture, inhibit 
carcinogenesis in mouse models of OSCC, and have been used both alone and in 
combination in clinical trials to treat oral leukoplakia and squamous cell carcinoma38-42.  
Aberrations in this pathway, including reductions in RARβ, RARγ, cellular retinoic acid  
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binding protein 2 (CRABP2), and lecithin:retinol acyltransferase (LRAT) mRNA and 
protein levels, as well as increases in cytochrome P450 26A1 (CYP26A1), the enzyme 
responsible for the first step of RA catabolism, are frequently observed in HNSCC5, 10, 
43-47.  
 Our work has identified another component of this pathway, ALDH1a2, that 
exhibits reduced expression in HNSCC. Endogenous ALDH1a2 catalyzes the 
intracellular synthesis of all-trans RA from all-trans retinaldehyde7. We observed 
reduced ALDH1a2 mRNA levels in human HNSCC patients through our examination 
of patient microarray data on Oncomine.com, and reductions in the protein levels of 
ALDH1a2 in cultured human HNSCC cell lines (Figures 2.1,2.2). These data are 
supported by a recent publication in which researchers reported that the ALDH1a2 
promoter is often hypermethylated in HNSCC patients with non-HPV-driven tumors48. 
Interestingly, this group also found that there is a strong correlation between high 
ALDH1a2 protein expression and greater overall and progression-free patient survival 
(Figure 1.4)48. Taken together, these results indicate that a reduction in ALDH1a2 
expression is a common event in HNSCC carcinogenesis. Because ALDH1a2 
synthesizes RA, a known stimulator of growth arrest, apoptosis, and differentiation, 
there is a logical pathogenic connection between loss of ALDH1a2 and carcinogenesis5. 
 In our phenotypic assays, we found that overexpression of TG ALDH1a2 and 
treatment with 1 µM RA had a similar effect on the growth of SCC-4, SCC-9, and SCC-
25 cells. To date, a large body of research has been conducted to evaluate the effects of 
treatment with RA on the phenotype of cultured human HNSCC cell lines in vitro. 
Numerous studies have found that RA treatment inhibits the proliferation and colony 
formation of many HNSCC cell lines, to varying degrees depending on the cell line12-
14, 18, 49. In addition, RA treatment has been observed to induce apoptosis and cell cycle 
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arrest in certain HNSCC cell lines; RA treatment induced apoptosis, as measured by 
DNA ladder formation, in human HNSCC lines UMSCC-17B, UMSCC-22A, UMSCC-
38, and 1438, and induced cell cycle G1 arrest in HNSCC cell lines SCC-1, SCC-9, 
YCU-N861 and YCU-H89150-52. Treatment of HNSCC cell lines with RA also inhibits 
squamous cell differentiation, as indicated by decreased expression of cytokeratin 1 
(K1), transglutaminase type 1, and involucrin following treatment with RA12, 14, 49. 
These three markers are frequently aberrantly overexpressed in HNSCC49. 
 Previous work has also demonstrated the efficacy of restoring retinoid signaling 
to inhibit SCC growth. Overexpression of CRABP2 via transfection in an esophageal 
SCC line with low endogenous CRABP2 expression (EC109) inhibited cell growth and 
migration and promoted apoptosis47. Retroviral transduction of RARβ2 into a HNSCC 
line that does not express endogenous RARβ (SqCC/Y1) made the cells much more 
sensitive to growth suppression by RA53, 54. Consistent with these data, we found that 
overexpression of ectopic ALDH1a2 in human SCC cell lines reduced their proliferation 
rate and colony formation ability (Figures 2.4, 2.5). To our knowledge we are the first 
to study the effect of increased ALDH1a2 expression on the neoplastically transformed 
phenotype of cultured human HNSCC lines.  
CONCLUSIONS 
 In the present study we have provided evidence that ALDH1a2 acts as a tumor 
suppressor in HNSCC. First, we have determined that reduced ALDH1a2 expression is 
a common event in HNSCC. Previous work has also identified a correlation between 
ALDH1a2 protein expression and improved patient clinical outcome48. Furthermore, we 
observed that overexpression of ectopic ALDH1a2 in SCC cell lines with low 
endogenous ALDH1a2 levels inhibits cell growth in vitro. In conclusion, this study 
indicates that enhanced ALDH1a2 has an inhibitory effect on HNSCC growth and 
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provides rationale for further research into the role of ALDH1a2 in HNSCC 
carcinogenesis in vivo.  
43 
 
SUPPLEMENTARY DATA 
 
 
pQC-ALDH1a2
(7.2 kb) 
Supplemental Figure 2.1: Schematic of the pQC-ALDH1a2 retroviral vector used to 
drive constitutive overexpression of ALDH1a2. The vector was constructed by inserting 
the AgeI fragment of pCMV-Sport6/ALDH1a2 into pQCXIP (Clontech Laboratories, 
Inc.). We verified correct insertion by enzyme digest and sequencing at the Cornell 
CORE Facilities.  
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Supplemental Figure 2.2: ALDH1a2 overexpression in OKF4 cells. We infected 
OKF4 cells with either empty pQC vector (+EV) or a vector driving constitutive 
expression of ALDH1a2 (pQC-ALDH1a2; +ALDH1a2; Supplemental Figure 2.1) and 
selected 7-10 days with puromycin before plating cells for experiments. At Day 0, one 
cohort of EV-infected OKF4 cells was treated with 1 µM RA. The other lines were 
treated with an equivalent volume of vehicle control. (A) RT-PCR analysis of parental 
OKF4 cells and infected OKF4 cells. We used primers specific for the transgenic (TG) 
ALDH1a2 transcript. HPRT1 was used as a loading control. Primer sequences are listed 
in Table 2.1. (B) Cell proliferation assay of infected OKF4 cells. Each data point 
represents the mean of n≥3 separate experiments (biological repeats) ±SEM. The data 
were analyzed using two-way ANOVA (C) Colony formation assay of infected OKF4 
cells. 
A 
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CHAPTER THREE 
GENERATION OF TRANSGENIC MICE WITH TETRACYCLINE-
INDUCIBLE EXPRESSION OF ALDH1A2 IN THE ORAL CAVITY 
EPITHELIUM 
 
INTRODUCTION 
Vitamin A (all-trans retinol) and its derivatives, retinoids, play a critical 
regulatory role in differentiation and proliferation during both embryonic development 
and adult tissue homeostasis1.  All-trans retinol is obtained from the diet, and is 
metabolized into its most biologically-active derivative, all-trans retinoic acid (RA), 
through the oxidization of retinaldehyde by aldehyde dehydrogenase 1a2 (ALDH1a2, 
formerly RALDH2). Intracellular lipid binding proteins such as cellular retinoic acid 
binding protein 2 (CRABP2) shuttle cytoplasmic RA to the nucleus2, 3. RA then 
signals by binding and activating specific nuclear receptors – retinoic acid receptors 
(RARs) and retinoid X receptors (RXRs) – thereby controlling the transcription of a 
wide assortment of target genes.4  
Endogenous retinoid signaling is essential for proper epithelial differentiation 
and function5. As a result, altering this signaling pathway has a profound phenotypic 
effect upon epithelial tissues such as the oral mucosa; vitamin A deficiency in 
experimental animals induces hyperplasia and squamous metaplasia in the oral 
mucosa6. This phenotype is similar to the histology observed in human patients with 
head and neck squamous cell carcinoma (HNSCC), a disease characterized by 
abnormal cellular differentiation, growth, and morphology of cells in the basal and 
suprabasal layers of the squamous epithelium in the oral cavity7. While the squamous 
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epithelium is normally a highly-ordered structure consisting of stratified layers of cells 
in distinct differentiation states, this organization is lost during HNSCC carcinogenesis 
as cells accumulate DNA mutations and epigenetic changes in critical genes and 
become dysregulated8, 9. Tumors in patients with HNSCC frequently exhibit 
compromised retinoid signaling resulting from aberrant expression of key members of 
the retinoid signaling pathway4, 7. Reductions in RARγ, RARβ2, CRABP2, and 
ALDH1a2 mRNA and protein levels have all been observed to be common events in 
HNSCC10-14. In addition, aberrant retinoid signaling has also been observed in 
psoriasis and melanoma, two disorders characterized by abnormal epithelial 
differentiation and hyperproliferation15, 16.  
Because endogenous retinoid signaling plays a critical role in preventing 
malignant dysregulation in the epithelium, restoring retinoid signaling through 
treatment with exogenous retinoids is a compelling therapeutic strategy17. Retinoids 
have proven effective at transiently suppressing oral premalignant lesions and second 
primary tumors (SPT) in HNSCC patients18. However, to date, pan-RAR retinoid 
therapies have not exhibited long-term efficacy in Phase III clinical trials of HNSCC19. 
Thus, further research into the proteins involved in endogenous retinoid synthesis and 
signaling could reveal new and more effective strategies for retinoid therapy.  
To this end, we sought to characterize further the role of the enzyme 
ALDH1a2 in the stratified squamous epithelium. ALDH1a2 (Gene ID: 8854) catalyzes 
an irreversible step of RA synthesis – the oxidation of retinaldehyde to RA – thereby 
playing a critical role in endogenous retinoid signaling. In our previous work, detailed 
in Chapter 2, we showed that ALDH1a2 mRNA levels are decreased in human 
HNSCC compared to normal tissue, and that ALDH1a2 protein levels are lower in 
cultured human HNSCC cell lines compared to immortalized but non-transformed 
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keratinocytes, suggesting that expression of ALDH1a2 is reduced during HNSCC 
carcinogenesis (Figures 2.1, 2.2). In addition, overexpression of ectopic ALDH1a2 in 
these HNSCC cell lines decreased proliferation and colony formation (Figures 2.4, 
2.5). These results indicate that ALDH1a2 inhibits the growth of neoplastically 
transformed HNSCC cells. 
To test how ALDH1a2 affects carcinogenesis development in vivo, here we 
describe the development of a Tet-On transgenic mouse system for the inducible 
expression of ALDH1a2 exclusively in the basal layers of select, stratified squamous 
epithelial tissues including the tongue, skin, and esophagus. In this model, we detect 
ALDH1a2 induction only in the presence of doxycycline (dox), indicating that this is 
an effective system for tightly-regulated expression of ALDH1a2 in target tissues. 
This new transgenic mouse model is a valuable tool for studies on retinoid signaling in 
normal and disease states of the epithelium. 
MATERIALS AND METHODS 
Construction of the TRE-ALDH1a2 transgene 
To generate the TRE-ALDH1a2 transgene, I released the mALDH1a2 cDNA 
from the pCMV-Sport6/ALDH1a2 vector (Clontech Laboratories, Inc.) by AgeI 
digest, and amplified it via PCR to generate BamHI and NotI restriction sites on the 5’ 
and 3’ ends, respectively. This fragment (1.5 kb) was then inserted into the 
BamHI/NotI sites of the pTRE2hyg expression vector (Cat. No. 631014; Clontech 
Laboratories, Inc.), placing ALDH1a2 downstream of the tetracycline response 
element (TRE) and CMV2 promoter, and upstream of a β-globin intron/poly(A) 
sequence (the full pTREhyg-ALDH1a2 construct is shown in Supplemental Figure 
3.1). I confirmed correct insertion by restriction enzyme digest and sequencing 
through the Cornell University Core Laboratories Center. I verified the inducibility of 
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the transgenic ALDH1a2 in the human keratinocyte line SCC-9 (Supplemental Figure 
3.2).  
Generation and treatment of transgenic mice 
We used two transgenic mouse lines, TRE-ALDH1a2, and K14-rtTA, in this 
Tet-On system. To create the TRE-ALDH1a2 mice, I freed the TRE-ALDH1a2 
expression cassette from the vector backbone by XhoI/SapI double partial digestion 
and purified it by gel electrophoresis using the QIAquick Gel Extraction Kit (Cat. No. 
28704; QIAGEN). I then sequenced the resulting fragment (3.3 kb), diluted it to 50 
ng/µL and submitted it to the Weill Cornell Medical College (WCMC) Transgenic 
Mouse Core Facility for microinjection into fertilized C57Bl/6 mouse eggs.  
I identified potential TRE-ALDH1a2 founder animals through Southern 
analyses. 10 µg of mouse tail genomic DNA was digested with EcoRI, separated on an 
agarose gel, and subjected to Southern blotting and hybridization using a Hybond-N 
membrane (Cat. No. 10600002; Amersham, GE Healthcare Life Sciences). 
Membranes were probed using the 32P-labeled 662 bp AatII - BsaI fragment of pTRE-
ALDH1a2 (for ALDH1a2), stripped, and re-probed using the 32P-labeled 673 bp 
EcoRI - NotI fragment (for the β-globin intron). I detected signals using a 
phosphoimager. From this analysis I identified three positive founders: #9, 11, and 25. 
I confirmed the presence of the transgene by genotyping PCR, using primers specific 
for the transgenic ALDH1a2 (Table 3.1). Each of the verified TRE-ALDH1a2 founder 
mice was then bred with C57Bl/6 wild-type mice to establish three independent TRE-
ALDH1a2 transgenic lines. I again confirmed positive progeny using both Southern 
blot and PCR, and all founders transmitted the transgene.  
The K14-rtTA transgenic line was originally generated in the laboratory of Dr. 
Elaine Fuchs, Rockefeller University20. I obtained a K14-rtTA founder mouse from 
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The Jackson Laboratory (Cat. No. 008099) (FVB-Tg(KRT14-rtTA)F42Efu/J), and 
genotyped it via PCR as described previously (primers listed in Table 3.1).21, 22 This 
K14-rtTA+/- mouse was crossed with TRE-ALDH1a2+/- females to generate 
bitransgenic K14-rtTA/TRE-ALDH1a2 mice, which I then tested for both transgenes 
using PCR. The resulting mice, and all mice used for the experiments herein, were 
thus 50/50 C57Bl/6 and FVB in genetic background. In addition, all TG-positive mice 
described in the present study were single-allele positive for the transgene(s) (K14-
rtTA+/-, TRE-ALDH1a2+/-, K14-rtTA+/-/TRE-ALDH1a2+/-). 
Doxycycline (dox; Cat. No. D9891; Sigma) was diluted to 2 mg/mL in the 
drinking water. Mice had free access to the water, which was changed every 2-3 days. 
I maintained all mice in the WCMC Research Animal Resource Center, and I 
performed all studies according to a protocol approved by the Institutional Animal 
Care and Use Committee (IACUC).  
 
Table 3.1: Primer sequences used for Genotyping PCR 
ǂ Primer sequences provided by Jackson Labs 
Gene Forward Primer  (5'-3') 
Reverse Primer  
(5'-3') 
Product 
Size 
ALDH1a2 gacttgtagcagctgtcttcact tcacccatttctctcccatttcc 160 bp 
rtTAǂ cacgatacacctgactagctgggtg catcacccacaggctagcgccaact 500 bp 
MβCasein gatgtgctccaggctaaagtt agaaacggaatgttgtggagt 500 bp 
 
Tissue dissection and immunostaining 
After terminating treatment, I sacrificed mice by cervical dislocation and 
performed dissection immediately. I harvested tissue samples and then snap froze 
them in liquid nitrogen (for RNA or protein isolation), or fixed them in 4% 
paraformaldehyde in phosphate-buffered saline (PBS) at 4°C overnight before transfer 
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to 70% ethanol for tissue processing and paraffin embedding at the WCMC Electron 
Microscopy and Histology Core Facility. All tissue sections were cut to 7 µm. I 
deparaffinized the sections with Histo-Clear II (Cat. No. HS-202; National 
Diagnostics) and rehydrated them in a graded series of ethanol. Next, I performed 
heat-induced antigen retrieval using Antigen Unmasking Solution (Tris-based, Cat. 
No. H-3301, for ALDH1a2 primary antibody; citrate-based, Cat. No. H-3300, for all 
other antibodies; Vector Laboratories) in a pressure cooker for 3 minutes. I then 
treated the sections with 3% hydrogen peroxide diluted in methanol for 10 minutes, 
before blocking with 5% normal goat serum (Cat No. S-1000; Vector Laboratories) in 
PBS (for rabbit primary antibodies), 5% normal horse serum (Cat. No. S-2000; Vector 
Laboratories) in PBS (for goat primary antibodies), or mouse anti-IgG blocking 
reagent (Cat. No. MKB-2213; Vector Laboratories) (for mouse primary antibodies) for 
30 minutes at room temperature. Sections were incubated with primary antibodies 
diluted in blocking solution overnight at 4°C. All primary antibodies used are 
described in Table 3.2. I then treated sections with secondary antibodies provided in 
the SuperPicture Polymer Detection Kit (Cat. No. 879263; Life Technologies) (for 
rabbit primary antibodies), ImmPRESS Reagent Kit (Cat. No. MP-7405; Vector 
Laboratories) (for goat primary antibodies), or Mouse on Mouse (MOM) Detection 
Kit (Cat. No. MKB-2213; Vector Laboratories) (for mouse primary antibodies).  
I conducted immunohistochemical (IHC) staining for ALDH1a2 using a 
custom rabbit anti-mouse ALDH1A2 polyclonal antibody generated for our lab by 
Alpha Diagnostics International. Specificity for ALDH1a2 was confirmed as 
described previously23. Neighboring tissue sections were stained with antibodies as 
listed in Table 3.2. 
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Table 3.2: Primary antibodies 
PC = polyclonal antibody; MC = monoclonal antibody 
ǂ A custom anti-ALDH1a2 antibody was generated for our lab by Alpha Diagnostics 
Target  Company Catalog # Lot # Source Dilution 
ALDH1a2 Alpha Diagnostics  N/A ǂ Batch #4 Rabbit PC 1:200 
CRABP2 Santa Cruz sc-10065 A2813 Goat PC 1:100 
EZH2 Cell Signaling 5246S 7 Rabbit PC 1:200 
K14 Novocastra Laboratories NCL-002 N/A Mouse MC 1:100 
 
RNA isolation and RT-PCR analysis 
I homogenized snap-frozen tissues in 1 mL TRIzol Reagent (Cat. No. 
15596018; Ambion, Thermo Fisher Scientific Inc.), and extracted RNA according to 
manufacturer’s protocol. I quantified RNA isolates using a NanoDrop 2000C (Thermo 
Fisher, Scientific, Inc.), and reverse transcribed 1 µg total RNA using the qScript 
cDNA Supermix (Cat. No. 95048; Quanta Biosciences). I diluted the resulting cDNA 
1:10, and used 2 µL as template for semi-quantitative RT-PCR reactions as previously 
described24. All primers used for RT-PCR are listed in Table 3.3. 
 
Table 3.3: Primer sequences used for RT-PCR 
ǂ Primer complementary to transgenic β-globin poly-A sequence 
Gene Forward Primer  (5'-3') 
Reverse Primer  
(5'-3') 
Product 
Size 
ALDH1a2 total gacttgtagcagctgtcttcact tcacccatttctctcccatttcc 160 bp 
ALDH1a2 TG gacttgtagcagctgtcttcact tgctcaaggggcttcatgatgtccǂ 467 bp 
rtTA tacactgggctgcgtattgg ccgctttcgcactttagctg 198 bp 
36B4 agaacaacccagctctggagaaa acaccctcccagaaagcgagagt 448 bp 
 
Statistical analysis of data 
All experiments consist of at least 3 independent biological replicates (n≥3). 
Statistical analyses were conducted using GraphPad Prism 6.0 software. I determined 
the means ± S.E.M. and compared independent populations using the Student’s t-test 
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or One-way ANOVA, as indicated. Differences with a p < 0.05 were considered 
statistically significant.  
RESULTS 
Generation of K14-rtTA/TRE- ALDH1a2 (KRT/ALDH) transgenic mice 
We utilized two transgenic constructs to generate the K14-rtTA/TRE-ALDH1a2 
Tet-On bitransgenic mice. One construct contained the murine Aldh1a2 inserted 
downstream from a minimal promoter and the tetracycline response element (TRE) 
(TRE-ALDH1a2), and the other contained the reverse tetracycline-controlled 
transactivator, rtTA2S-M2-VP16 (rtTA), under the control of the truncated human 
cytokeratin 14 (K14) promoter (K14-rtTA) (Figure 3.1). This K14 promoter is 
specifically active in the basal layer of some stratified squamous epithelia – such as 
the oral cavity and skin – thus driving the constitutive and tissue-specific expression of 
rtTA 25-28. In this Tet-On system, the TRE allows expression of the transgenic 
mALDH1a2 in the presence of doxycycline (dox)-activated rtTA (Figure 3.1).  
Figure 3.1: The Tet-On inducible system. A simplified schematic of the K14-rtTA 
and TRE-ALDH1a2 constructs utilized in this Tet-On inducible transgenic mouse 
system. The truncated K14 promoter drives rtTA expression in the basal layer of 
certain stratified squamous epithelia, and the TRE dictates that transgenic ALDH1a2 
expression is induced in the presence of doxycycline (dox).  
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We identified a total of three positive TRE-ALDH1a2 founder mice by 
Southern blot using a probe directed at the β-globin intron: mice #9, 11, and 25 
(Figure 3.2A). We observed multiple bands in each positive founder, indicative of 
multiple copy insertion, and the presence of a band lower than expected (<2.2 kb) 
suggests that fragmentation occurred. Using primers specific for transgenic (TG) 
ALDH1a2, we confirmed the presence of the transgene by genotyping PCR (Figure 
3.2B). In order to generate three genetically-distinct, independently-derived TRE-
ALDH1a2 lines, we crossed each of the three TRE-ALDH1a2 founder mice with a WT 
C57Bl/6 mouse and again identified positive progeny by both Southern blot and PCR 
analysis (data not shown). We then crossed female F1 generation TRE-ALDH1a2+/- 
mice with a male K14-rtTA+/- mouse obtained from Jackson Labs to generate three 
independent K14-rtTA+/-/TRE-ALDH1a2+/- (KRT/ALDH) lines. We used genotyping 
PCR to confirm the presence of the transgenes in each KRT/ALDH litter (Figure 3.2C). 
Tissue-specific, dox-inducible ALDH1a2 expression in KRT/ALDH mouse lines 
We treated 6-8 week-old bitransgenic KRT/ALDH mice from each line with 2 
mg/mL dox or vehicle control (water) in the drinking water for 48 hours. Littermate 
mice that were negative for one or both transgenes were also treated. We detected 
rtTA transcripts in the esophagus, tongue, and skin of mice from all three KRT/ALDH 
lines by RT-PCR (Figure 3.3A).  By quantification of the bands we observed that rtTA 
mRNA was approximately 4 to 30-fold higher in the tongue and 10 to 60-fold higher 
in the skin as compared to esophagus. This is consistent with previously reported data 
on the relative activity of the truncated K14 promoter in different squamous epithelial 
tissues25. Both the #11 and #25 KRT/ALDH lines exhibited expression of transgenic 
(TG) ALDH1a2 transcript in the esophagus, tongue, and skin during treatment with  
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dox (Figure 3.3A, middle and right panels). Notably, we observed lower TG 
ALDH1a2 transcript levels in the esophagus compared to the tongue and skin, most 
likely attributable to the lower rtTA expression in this tissue. No TG ALDH1a2 or 
rtTA mRNA was detected in lung, liver, or kidney samples, illustrating the tissue-
specificity of this expression system (Figure 3.3A). We could not detect any TG 
ALDH1a2 mRNA in the #9 KRT/ALDH line, in contrast to lines #11 and 25 (Figure 
1A, left panel). We also did not detect any TG ALDH1a2 transcript expression in 
untreated mice and in dox-treated mice that did not carry both transgenes (data not 
shown). We found that the #11-line achieved greater average TG ALDH1a2 transcript 
expression (approximately 3-fold) after 48 hours of dox treatment compared to 
bitransgenic #25 line KRT/ALDH mice (Figure 3.3B). Together, our results show that 
this Tet-On expression system is both highly tissue-specific and dox-inducible. We 
performed additional experiments on the #11 KRT/ALDH line, as line #11 exhibited 
the greatest dox-induction of the TG ALDH1a2 transcript. 
We utilized IHC analysis to examine total (endogenous + TG) ALDH1a2 
protein levels following dox treatment, and to determine its localization within the 
target tissues. We detected ALDH1a2-positive cells in the epithelium of the tongue, 
skin, and esophagus of KRT/ALDH mice after 72 hours dox (brown stain, Figure 
3.4A). Consistent with the RT-PCR results shown in Figure 3.3, we observed lower 
ALDH1a2 protein expression in the esophagus as compared to the tongue and skin 
(Figure 3.4B). We detected no changes in ALDH1a2 protein levels in the liver and in 
the tissue sections of dox-treated littermate K14-rtTA+/- (KRT) mice (Figure 3.4A, top 
row). The staining pattern and intensity of stain of endogenous ALDH1a2, as observed 
in the KRT mice (Figure 3.4A, left column), are consistent with previously reported 
data on ALDH1a2 protein expression in different human tissues 
(www.proteinatlas.org, accessed September 26, 2016). 
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In these transgenic mice rtTA expression is driven by a truncated K14 
promoter. Therefore, in this model K14-expressing cells constitutively express rtTA 
and will express TG ALDH1a2 upon dox addition. IHC staining of endogenous K14 
protein revealed high K14 expression specifically in the basal layers of the tongue and 
esophagus (Figure 3.4C). These data are consistent with previously reported 
expression patterns of K14 in these tissues29.  In contrast, ALDH1a2 protein 
expression following dox treatment was not confined to the basal layer; while the 
majority of cells  in the basal layer are ALDH1a2-positive following a 72 hr dox 
treatment (approx. 96.9% (± 2.0%)), some cells in the suprabasal layers also stained 
dark brown for ALDH1a2 (Figure 3.4A). This result suggests that TG ALDH1a2 
expression persists even after the cells move upward through the epithelium and K14 
expression decreases. Notably, we observed no change in K14 protein levels following 
TG ALDH1a2 induction by dox in #11 KRT/ALDH mice (data not shown). 
Dox-inducible TG ALDH1a2 mRNA and protein over time 
To characterize the dox-inducible expression of TG ALDH1a2 in the tongue 
epithelium further, we conducted time course experiments in which we treated 
bitransgenic #11 KRT/ALDH mice and singly-transgenic littermate KRT mice, used as 
negative controls, with dox for 24, 48, and 72 hours. We found that TG ALDH1a2 
transcript levels in the tongue were maximal by 72 hours of dox treatment, while rtTA 
Figure 3.4: ALDH1a2 protein is specifically induced in squamous epithelial 
tissues. 6-8 week-old KRT and KRT/ALDH mice were treated with dox (2 mg/mL) in 
the drinking water for 72 hours. (A,B) Paraffin-embedded tissue sections were stained 
with 1:200 ALDH1a2 antibody, except for no primary control sections. Fields shown 
are representative images from one of n≥3 mice of each genotype. Boxed regions in 
esophagus panels of (A) are displayed at higher magnification in (B). Black arrows 
indicate positively-stained cells in the esophageal epithelium. (C) Tissue sections were 
stained with 1:100 K14 antibody. Fields shown in (C) are representative images from 
one control mouse. Images in A,C taken at 200X, scale bar represents 100 µm. Images 
in B taken at 400X, scale bar represents 50 µm. All images shown are representative 
of ≥4 fields of each section. Primary antibody details are provided in Table 3.2. 
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mRNA levels remained constant (Figure 3.5A). We used different primer pairs to 
evaluate TG ALDH1a2 mRNA and total (endogenous + TG) ALDH1a2 mRNA levels, 
and observed that the TG ALDH1a2 transcript levels after dox treatment are 
representative of the total transcript levels of ALDH1a2 present in the tongue tissue. 
Upon removal of dox from the drinking water, ALDH1a2 transcript levels (TG and 
total) decreased steadily over a period of 2-3 days (Figure 3.5A). 
We also observed ALDH1a2-postive cells in the basal layer of the tongue 
epithelium as early as at 48 hours of dox treatment using IHC (Figure 3.5B, second 
panel). By 72 hours, most of the basal layer cells (96.9% (± 2.0%)) and some cells in 
the suprabasal layers were positive for ALDH1a2 (Figure 3.5B, third panel). Adjacent 
tongue muscle tissue exhibited no changes in ALDH1a2 staining. After removal of 
dox, the percentage of ALDH1a2-positive cells in the basal layer decreased to 54.8% 
(± 5.3%) by 24 hrs and 19.5% (± 1.3%) by 48 hrs (Figure 3.5B, fourth and fifth 
panels). We also detected increased staining for ALDH1a2 in the suprabasal layers at 
these time points compared to earlier time points (down arrows, Figure 3.5B). Taken 
together with the data shown in Figure 3.4, these results indicate that the TG 
ALDH1a2 signal originates in K14-positive, basal layer progenitor cells, and that 
these cells maintain TG ALDH1a2 expression as they differentiate and move upward 
through the suprabasal layers30. Overall, these data demonstrate the inducibility, 
reversibility, and tissue specificity of TG ALDH1a2 expression in KRT/ALDH 
transgenic mice.  
CRABP2 protein level is increased in tongue epithelia following ALDH1a2 induction 
 To determine whether TG ALDH1a2 enhances endogenous intracellular RA 
signaling, we utilized LC-MS to directly measure retinoid levels in the tongues of KRT 
and KRT/ALDH mice following dox treatment. Ultimately, this analysis was  
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inconclusive, as discussed in detail in the Appendix (Figures A.2, A.3). In addition, 
our LC-MS experiments can not delineate the effects of ALDH1a2 induction 
specifically in loci of interest, such as the tongue epithelium, because we analyzed 
whole tongues by LC-MS. We therefore used IHC to stain for CRABP2; the function 
of endogenous CRABP2 is to facilitate retinoid signaling by binding free cytoplasmic 
RA and shuttling it to the nucleus for binding and activation of RAR/RXR receptors31, 
32. CRABP2 is downstream of ALDH1a2 in the classical retinoid metabolism and 
signaling pathway (Figure 1.2). In addition, CRABP2 expression is increased by RA33, 
34. We treated #11 KRT/ALDH mice and KRT mice with dox for 7 days (1 week) and 
stained for CRABP2 protein (Figure 3.6). We found that the tongue epithelia of 
KRT/ALDH mice showed greater CRABP2 protein expression than those of KRT mice 
in terms of mean stain intensity (1.35-fold change ± 0.12, p=0.0442; Figure 3.6B). As 
CRABP2 is an integral member of the RA signaling pathway and is induced by RA, 
these data provide strong, though indirect evidence for increased RA synthesis and 
signaling after TG ALDH1a2 induction by dox in #11 KRT/ALDH TG mice.  
Exogenous ALDH1a2 reduces EZH2 protein levels in the tongue epithelium 
 Enhancer of zeste homolog 2 (EZH2) is an epigenetic regulatory protein that 
functions as a transcriptional repressor as a core component of the polycomb 
repressive complex 2 (PRC2)35. EZH2 is overexpressed in numerous malignancies, 
including HNSCC, in which it has been proposed as a potential drug target36. Previous 
research in our lab has demonstrated that RA signaling decreases the activity of PRC2 
(and EZH2) by stimulating the dissociation of PRC2 from the promoters of target 
genes35, 37, 38. In addition, experiments in mouse embryonic stem cells (CCE) revealed 
that EZH2 mRNA and protein levels are decreased following treatment with RA39. We 
therefore investigated whether TG ALDH1a2 overexpression in the tongue epithelia of  
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Figure 3.6: Tongue CRABP2 protein levels are increased following ALDH1a2 
overexpression. IHC analysis of tongue sections from KRT (K14-rtTA+/-) and 
KRT/ALDH (K14-rtTA+/-/TRE-ALDH1a2+/-) mice treated with dox (2 mg/mL) or 
vehicle control (water) for 1 week (7 days). All mice shown in this figure are from 
the #11 KRT/ALDH line. Sections were incubated with 1:100 anti-CRABP2 
(Table 3.2). Sections incubated without primary antibodies were used as negative 
controls. (A) Images shown are representative of at least 4 fields from each of n≥3 
mice from each group. Brown color indicates positively stained cells. Images were 
taken at 200X and 400X, as indicated. Scale bars represents 100 µm and 50 µm, 
respectively. (B,C) Quantification of CRABP2 staining in tongues using Image J 
software. We analyzed n=4 fields of a stained tongue section from each mouse. 
Bars represent mean ±S.E.M. of n=3 mice from each group. (B) Each field was 
analyzed for the mean pixel intensity (AU). (C) Quantification of the percent area 
of the tongue epithelium that stained positive for CRABP2 protein. The data were 
analyzed using a Student’s t-test; ⁎ indicates p<0.05. 
69 
 
KRT/ALDH mice affects EZH2 expression. We treated line #11 KRT and KRT/ALDH 
mice with dox for 1 and 4 weeks and stained for EZH2 protein using IHC. Staining for 
EZH2 was greatest in basal layer cells (brown stain, Figure 3.7). We used ImageJ 
software to quantify the mean intensity of the stain and the percent of the epithelium in 
each field that stained positively for EZH2. We did not observe a significant change in 
EZH2 protein levels after 1 week of dox treatment. However, we observed decreased 
staining for EZH2 protein in the tongue epithelia of KRT/ALDH mice compared to 
KRT mice after 4 weeks of dox treatment: mean stain intensity was decreased by 1.47-
fold (p=0.0164) and the percent positive epithelial area was decreased by 1.38-fold 
(p=0.007) (Figure 3.7). These results suggest that ectopic, TG ALDH1a2 leads to a 
reduction in EZH2 in the tongue epithelium. This is an interesting observation that is 
explored further in Chapter 4.  
DISCUSSION 
In this chapter we describe the generation of a novel bitransgenic mouse 
system that allows for the inducible expression of ALDH1a2 specifically in certain 
stratified squamous epithelial tissues: the tongue, skin, and esophagus. This tissue-
specificity is accomplished through the use of a truncated human K14 promoter, first 
generated and utilized by Fuchs et al28. This truncated K14 promoter has been used by 
our lab and others to express various transgenes in the basal cells21, 26, 27, 40-42. 
Endogenous K14 is expressed exclusively in the basal layer of the normal epithelium, 
which is the innermost epithelial layer and adjoins the basement membrane (Figure 
1.2). The basal layer contains a stem cell population that is long-lived, highly 
proliferative, and responsible for repopulating the regenerating epithelium43. In 
addition, these cells are the site of origin of squamous cell carcinomas of the skin and  
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Figure 3.7: Tongue EZH2 protein levels are decreased following ALDH1a2 
overexpression. IHC analysis of tongue sections from line #11 KRT (K14-rtTA+/-) 
and KRT/ALDH (K14-rtTA+/-/TRE-ALDH1a2+/-) mice treated with dox (2 mg/mL) 
or vehicle control (water) for 1 or 4 weeks, as indicated. Tissue sections were 
incubated with 1:200 anti-EZH2 primary antibody. Primary antibody information 
is provided in Table 3.2. (A) Images shown are representative of at least 6 fields 
from each of n≥3 mice from each treatment group. Brown color indicates 
positively stained cells. All mice shown in this figure are from the #11 
KRT/ALDH line. Images were taken at 200X and 400X, as indicated. . Scale bars 
represents 100 µm and 50 µm, respectively. (B,C) Quantification of EZH2 staining 
in tongues using Image J software. We analyzed n=3 fields of stained tongue 
section from each mouse. Bars represent mean ±S.E.M. of n=3 mice from each 
group. (B) Each field was analyzed for the mean pixel intensity (AU). We set the 
Y-axis minimum to the minimum detectable stain intensity (y=94). (C) 
Quantification of the percent area of the tongue epithelium that stained positive for 
EZH2 protein. The data were analyzed using One-way ANOVA; ⁎ 
indicates p<0.05, ⁎⁎ indicates p<0.01. 
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oral cavity30, 43, 44. These characteristics make K14-postive cells of particular interest 
for study in the context of epithelial malignancies.  
 Our bitransgenic mouse system utilizes a modified Tet-On expression system. 
To date, the Tet-On system has proven a powerful and elegant experimental tool for 
inducible and reversible transgene expression45. This temporal control allows us to 
rapidly induce and terminate TG ALDH1a2 transcript and protein expression through 
administration and removal of dox, respectively. Using this expression system, we 
were able to detect TG ALDH1a2 transcript and protein induction in the tongue 
epithelium by 48 hours of dox treatment (Figures 3.2, 3.4). By 72 hours of dox 
administration, ALDH1a2 induction was maximal and most of the epithelial basal 
layer cells stained positive for ALDH1a2 protein (Figures 3.3, 3.4). Li, et al. generated 
bitransgenic mice containing the K14-rtTA cassette to drive dox-inducible GFP in the 
tongue epithelium, and found that GFP was distributed throughout the dorsal surface 
of the tongue after 72 hours of dox administration via the drinking water46.   
We observed increased CRABP2 protein levels in tongue epithelia following 
induction of ALDH1a2 (Figure 3.5). CRABP2 is an intracellular lipid binding protein 
that binds and translocates free RA, and is known to exhibit increased expression in 
response to RA31, 33. CRABP2 is considered to be an indicator of RA activity in 
epithelial tissues such as the epidermis47, 48. Therefore, our results suggest that the 
dox-inducible expression of TG ALDH1a2 increases intracellular RA. This result is of 
particular clinical interest, as loss of CRABP2 expression is observed in squamous cell 
carcinomas and has been found to promote carcinogenesis13, 49. For this reason, 
restoration of CRABP2 signaling has been proposed as a therapeutic strategy in 
treating squamous cell carcinomas49.  
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An interesting finding of our study is that ectopic TG ALDH1a2 decreases 
EZH2 protein levels in tongue epithelia (Figure 3.6). EZH2, a H3K27 
methyltransferase, is a Polycomb group protein35. This group of proteins plays a 
critical role in controlling stem cell activity and differentiation in normal epidermal 
keratinocytes50. Previous research in mouse embryonic stem cells showed that EZH2 
mRNA and protein levels are reduced by RA; therefore the reduction in EZH2 protein 
levels we observe in dox-treated KRT/ALDH mice suggests that TG ALDH1a2 
increases intracellular RA signaling39. In addition, EZH2 is frequently overexpressed 
in several human epithelial cancer types, including HNSCC51. Zhou et. al. analyzed 
HNSCC patient RNAseq data available from the Cancer Genome Atlas (TCGA), and 
found that high EZH2 mRNA was associated with worse overall patient survival and 
advanced tumor grade36. In cell cultures, EZH2 overexpression promotes tumor cell 
proliferation, epithelial-mesenchymal transition (EMT), invasion and migration36, 51-54.  
Conversely, inhibition or depletion of EZH2 induces apoptosis and inhibits cell 
proliferation, colony formation, migration, and invasion in tongue squamous cell 
carcinoma cells55, 56.  To date, EZH2 has been proposed as a critical biomarker for 
diagnosis, a prognostic indicator, and a novel drug target in HNSCC55.  
CONCLUSIONS 
Taken together, our data show that the K14-rtTA/TRE-ALDH1a2 mouse line 
(#11) is an effective system for the tissue-specific induction of exogenous ALDH1a2. 
This mouse line is a powerful experimental tool for in vivo studies on RA synthesis in 
the context of the stratified squamous epithelium. In addition, our findings that ectopic 
TG ALDH1a2 expression in the tongue epithelium increases CRABP2 expression and 
decreases EZH2 expression evidence a role for ALDH1a2 in intracellular RA 
signaling. The effects of ALDH1a2 induction on CRABP2 and EZH2 are particularly 
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interesting in the context of HNSCC, and support our subsequent work in which we 
utilized our KRT/ALDH mice in a murine model of oral cavity squamous cell 
carcinoma (OSCC), as described in Chapter 4. 
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SUPPLEMENTAL DATA  
 
  
Supplemental Figure 3.1: Schematic of the pTRE-ALDH1a2 construct used to 
drive inducible expression of ALDH1a2. The vector was constructed by digesting 
pCMV-Sport6/ALDH1a2 with AgeI, and amplifying the resulting fragment to 
generate BamHI/NotI restriction sites for insertion into the BamHI/NotI sites of 
pTRE2hyg (Clontech Laboratories, Inc.). The resulting plasmid was verified by 
enzyme digest, and by sequencing at the Cornell CORE Facility. 
Supplemental Figure 3.2: Verification of inducibility of pTRE2-ALDH1a2 in 
keratinocyte line SCC-9 via RT-PCR. SCC-9 cells were first stably transfected 
with pUHD172-1neo, which drives constitutive expression of rtTA. Six stable 
clones were then generated after transfection with pTRE-ALDH1a2. These clones 
were treated with dox (1 mg/mL) for 48 hrs, before harvest and RNA isolation as 
previously described. Primers used for TG ALDH1a2 are specific to the transgenic 
(not endogenous, TG) transcript. HPRT1 was used as a loading control. Data shown 
is from one representative clone. Primers used are listed in Table 3.2. 
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CHAPTER FOUR 
OVEREXPRESSION OF ALDH1A2 IN THE TONGUE BASAL EPITHELIAL 
LAYER DURING ORAL SQUAMOUS CELL CARCINOMA 
CARCINOGENESIS  
 
INTRODUCTION 
Head and neck squamous cell carcinoma (HNSCC) is one of the most common 
human neoplasms worldwide, with an estimated 550,000 new cases and 300,000 
deaths globally each year1. While treatment of primary tumors with radiation and/or 
surgery is often successful, high rates of second primary tumor (SPT) development 
and recurrence complicate treatment and contribute to an overall 5-year survival rate 
of ~55%2. In addition, despite recent advances in biology and medicine, there are 
currently few chemotherapeutic options of limited clinical efficacy available for the 
treatment of HNSCC3. It is therefore imperative that we further our understanding of 
HNSCC carcinogenesis at the molecular level in order to develop new and more 
efficacious strategies for prevention and therapy. 
One of the major subtypes of HNSCC is oral cavity squamous cell carcinoma 
(OSCC), for which the primary etiological factors are long-term and excessive tobacco 
and/or alcohol use4. Repeated exposure to these carcinogens results in genetic, 
epigenetic, and metabolic changes to the epithelium of the oral cavity5. As these 
changes accumulate, the epithelium develops oral premalignant lesions and eventually, 
squamous cell carcinoma and metastatic cancer2. Another subtype of HNSCC is 
driven by human papilloma virus (HPV) infection; this subtype is comprised primarily 
of oropharyngeal cancers4. We are focused on non-HPV-related OSCC. 
82 
 
To date, retinoids – a group which includes the natural and synthetic 
derivatives of vitamin A (retinol) – are some of the best-studied agents in the 
treatment and prevention of SPT and recurrence in HNSCC6. The chemopreventive 
functions of retinoids are mediated through their binding to and subsequent activation 
of specific nuclear receptors, including the retinoic acid receptors (RARs) and retinoid 
X receptors (RXRs)6. Activation of RAR/RXRs by retinoids causes the dissociation of 
corepressors and the initiation of transcription of a wide assortment of target genes 
that control many critical cellular processes such as cellular proliferation, 
differentiation, and apoptosis7. Numerous studies have found that retinoids modulate 
cell differentiation and decrease proliferation of human HNSCC cells in vitro, and 
inhibit carcinogenesis in mouse models of OSCC 6, 8-10. When tested in humans, 
retinoids were efficacious in suppressing oral premalignant lesions and SPTs in both 
HNSCC and lung cancer patients6. However, despite their considerable 
chemopreventive and chemotherapeutic success in preclinical and clinical trials, 
retinoids do not exhibit long-term efficacy in preventing oral cavity cancer when given 
orally as a single drug in Phase III clinical trials 11. This paradoxical lack of clinical 
efficacy calls for greater research into the molecular mechanisms and pharmacology of 
retinoids in HNSCC, and investigation into novel retinoid therapy options12, 13. 
The most biologically-active derivative of retinol, all-trans retinoic acid (RA), 
is synthesized intracellularly primarily by aldehyde dehydrogenase 1a2 (ALDH1a2)14-
16. Decreased ALDH1a2 expression has been observed in numerous cancers, including 
prostate cancer, ovarian cancer, and HNSCC17-20. Researchers found that restoration of 
ALDH1a2 expression via transfection in human prostate cancer cells impaired colony 
formation18. Conversely, in a xenograft model of HNSCC, ALDH1a2 knockdown 
resulted in accelerated tumor growth21. Clinically, high ALDH1a2 mRNA and protein 
expression correlated with better overall survival in breast cancer and HNSCC 
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patients20, 22. In our previous work, described in Chapter 2, we also found that 
overexpression of ALDH1a2 inhibited the proliferation and colony formation of 
several SCC cell lines (Figures 2.5, 2.6). Taken together, these data suggest that 
ALDH1a2 is a candidate tumor suppressor in the pathogenesis of several cancers, 
including HNSCC. However, the role of ALDH1a2 in HNSCC carcinogenesis has yet 
to be elucidated.  
In this study we investigated the effects of ectopic ALDH1a2 expression on the 
development and progression of HNSCC in vivo during carcinogenesis. To this end, 
we generated a bitransgenic mouse (K14-rtTA/TRE-ALDH1a2) for the inducible and 
tissue-specific overexpression of ALDH1a2 in the basal layer of the tongue 
epithelium, as detailed in Chapter 3. Researchers in our lab have previously developed 
a murine model of OSCC in which the carcinogen 4-nitroquinoline 1-oxide (4-NQO) 
in drinking water is administered to mice over a period of 10 weeks23. The oral SCCs 
observed in this murine model are molecularly, histologically, and morphologically 
very similar to human SCCs23. Furthermore, research in our lab has shown that 
carcinogenesis in the 4-NQO model of OSCC is inhibited by treatment with 
exogenous retinoids24, 25. Therefore, this mouse carcinogenesis model is an ideal 
system in which to test the function of the RA-synthesizing enzyme ALDH1a2 during 
carcinogenesis. Herein, we describe the molecular and phenotypic effects of ectopic 
ALDH1a2 overexpression on 4-NQO-induced OSCC carcinogenesis. 
MATERIALS AND METHODS 
Animals and treatments 
I used 8-12 week-old female mice in this experiment: 20 K14-rtTA+/-/TRE-
ALDH1a2+/- (KRT/ALDH) bitransgenic mice, and 20 littermate control mice positive 
for the K14-rtTA+/- (KRT) transgene only. Genotypes of all mice were determined by 
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PCR as previously described (Chapter 3). I maintained all mice under controlled 
conditions, with a daily 12 hour light/dark cycle and access to normal chow (Lab-diet 
with constant nutrition, Lab-Diet Co.). I treated 10 mice of each genotype (20 total) 
with 100 µg/mL 4-NQO (Sigma, St. Louis, MO, USA) and 2 mg/mL doxycycline 
(dox) in their drinking water for 10 weeks (4N+Dox). I treated the remaining 20 mice 
with 2 mg/mL dox and propylene glycol vehicle control (VC) for 10 weeks 
(VC+Dox). I prepared 4-NQO and dox fresh each week throughout the entire 
treatment, and changed the drinking water weekly. Following 10 weeks of 4-NQO 
treatment, all mice were switched to drinking water containing 2 mg/mL dox alone 
and monitored for cancerous lesion development and weight loss. Eleven weeks after 
the termination of the 4-NQO treatment, two 4N+Dox-treated mice had died, and 
many of the remaining mice exhibited weight loss and large, visible lesions on their 
tongues. Therefore, mice were sacrificed at this time. This end point (21 weeks) is 4 
weeks earlier than our standard protocol because these mice exhibited an accelerated 
rate of 4-NQO-induced carcinogenesis compared to the mice in our previous studies23, 
26. This difference in response to 4-NQO is likely due to the genetic background of the 
KRT and KRT/ALDH mice (50/50 C57Bl/6/FVB). A simplified schematic of the 
treatment protocol is shown in Figure 4.1A. All studies were carried out according to a 
protocol approved by the WCMC Institutional Animal Care and Use Committee 
(IACUC). 
Tissue dissection, grading, and pathology 
I sacrificed the mice by cervical dislocation, and tissues were dissected 
immediately. I photographed whole tongues and esophagi, counted gross visible 
lesions, and graded the lesions 0-5 in a blinded manner as previously described (0 
indicating no lesions, and 5 being the most severe)23, 26. Tongues and esophagi were 
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cut in thirds longitudinally, and the middle third fixed in freshly-made 4% 
paraformaldehyde (in PBS) overnight at 4°C before tissue processing and paraffin 
embedding at the WCMC Electron Microscopy and Histology Core Facility. Sectioned 
tissue samples (cut to 7 µm) were stained with hematoxylin and eosin (H&E), and 
examined by pathologist Dr. Theresa Scognamiglio for squamous neoplasia. The 
lesions observed were classified as epithelial hyperplasia, dysplasia (mild, moderate, 
A 
B 
Figure 4.1: Experimental design of the 4-NQO treatment experiment. (A) A 
simplified diagram of the treatment protocol. A total of 40 mice were treated with 
doxycycline (dox; 2 mg/mL) plus 4-NQO (100 µg/mL) (4N+Dox) or dox plus vehicle 
control (VC+Dox) for 10 weeks. All mice were then switched to dox alone (2 
mg/mL) until sacrifice at 21 weeks. At this point lesions were counted and graded, 
and tissues were harvested as described. (B) Final body weights of the 18 surviving 
4N+Dox mice at the time of sacrifice. Error bars represent mean ±SEM. Analyses 
revealed no significant difference in final body weights between 4N+Dox KRT and 
KRT/ALDH mice. 
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or severe), carcinoma in situ, and squamous cell carcinoma, as previously described23, 
26. The remaining two thirds of each tongue were snap-frozen in liquid nitrogen and 
stored at -80°C for long-term storage.  
Immunohistochemistry 
I analyzed protein expression by immunohistochemistry (IHC) as previously 
described26, 27. Paraffin-embedded sections were deparaffinized with Histo-Clear II 
(National Diagnostics, Atlanta, Georgia, USA), rehydrated using a graded series of 
ethanol, and antigen retrieval was performed using Antigen Unmasking Solution (Tris-
based, Cat. No. H-3301, for ALDH1a2 primary antibody; citrate-based, Cat. No. H-
3300, for all other antibodies; Vector Laboratories, Burlingame, CA) in a pressure 
cooker for 3 minutes. I then quenched endogenous peroxidase activity with 3% 
hydrogen peroxide diluted in methanol for 10 minutes, before blocking with 5% 
normal goat serum (Cat No. S-1000; Vector Laboratories) in PBS (for rabbit primary 
antibodies), 5% normal horse serum (Cat. No. S-2000; Vector Laboratories) in PBS 
(for goat primary antibodies), or mouse anti-IgG blocking reagent (Cat. No. MKB-
2213; Vector Laboratories) (for mouse primary antibodies) for 30 minutes at room 
temperature. Sections were incubated with primary antibodies diluted in blocking 
solution overnight at 4°C (primary antibodies are described in Table 4.1). I used 
sections incubated without primary antibodies as negative controls. I utilized the 
secondary antibodies and staining reagents and protocols of the SuperPicture Polymer 
Detection Kit (Cat. No. 879263; Life Technologies) (for rabbit primary antibodies), 
ImmPRESS Reagent Kit (Cat. No. MP-7405; Vector Laboratories) (for goat primary 
antibodies), or Mouse on Mouse (MOM) Detection Kit (Cat. No. MKB-2213; Vector 
Laboratories) (for mouse primary antibodies).  
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To quantify IHC staining, I utilized ImageJ software (National Institutes of 
Health) to detect positive area (brown stain). I used a protocol adapted from “Basic 
Intensity Quantification with ImageJ” (University of Chicago; available online at: 
https://www.unige.ch/medecine/bioimaging/files/1914/1208/6000/Quantification.pdf). 
Mean pixel intensity was normalized to the minimum detectable staining intensity of 
each stained set of slides. 
 
Table 4.1: Primary antibodies 
PC = polyclonal antibody; MC = monoclonal antibody 
ǂ A custom anti-ALDH1a2 antibody was generated for our lab by Alpha Diagnostics 
Target  Company Catalog # Lot # Source Dilution 
ALDH1a2 Alpha Diagnostics  N/A ǂ Batch #4 Rabbit PC 1:200 
-Actin Millipore MAB1501 2665057 Mouse MC 1:80,000 
CRABP2 Santa Cruz sc-10065 A2813 Goat PC 1:100 
EZH2 Cell Signaling 5246S 7 Rabbit PC 1:200 
K14 Novocastra Laboratories NCL-002 N/A Mouse MC 1:100 
Vimentin Santa Cruz sc-7557 H1514 Goat PC 1:200 
 
RNA isolation and RT-PCR analysis 
Snap-frozen tissue was homogenized in 1 mL TRIzol Reagent (Cat. No. 15596018; 
Ambion, Thermo Fisher Scientific Inc.) for RNA extraction following the 
manufacturer’s protocol. Total RNA was quantified using a NanoDrop 2000C 
(Thermo Fisher, Scientific, Inc.), and 1 µg RNA was reverse transcribed using the 
qScript cDNA Supermix (Cat. No. 95048; Quanta Biosciences). Resulting cDNA was 
diluted 1:10, and 2 µL used as template for semi-quantitative RT-PCR (SQ-PCR) as 
previously described28. All primers used are listed in Table 4.2. I detected transgenic 
ALDH1a2 transcript using the ALDH1a2 forward primer and a reverse primer specific 
to the β-globin poly-A region of the transgenic cassette (Table 4.2).  
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Table 4.2: Primer sequences used for RT-PCR 
ǂ Primer complementary to transgenic β-globin poly-A sequence 
Gene Forward Primer  (5'-3') 
Reverse Primer  
(5'-3') 
Product 
Size 
ALDH1a2 gacttgtagcagctgtcttcact tcacccatttctctcccatttcc 160 bp 
ALDH1a2 TG gacttgtagcagctgtcttcact tgctcaaggggcttcatgatgtccǂ 467 bp 
rtTA tacactgggctgcgtattgg ccgctttcgcactttagctg 198 bp 
36B4 agaacaacccagctctggagaaa acaccctcccagaaagcgagagt 448 bp 
 
Western blot analysis 
 I homogenized snap-frozen tissues in final sample buffer (0.5 M Tris–HCl, pH 
6.8, 10% glycerol and 1% SDS) containing protease inhibitors (cOmplete Mini 
Protease Inhibitor Cocktail Tablets, Cat. No. 11836153001; Roche). Samples were 
boiled before quantification of total protein using the DC Protein Assay (Cat. No. 500-
0112; Bio-Rad). I separated 25 µg total protein on SDS-PAGE gels and transferred 
protein onto nitrocellulose membranes as previously described27. After blocking 
membranes in 5% skim milk in Tris-buffered saline containing 0.1% TWEEN 20 (Cat. 
No. P1379; Bio-Rad) (TBST) for 1 hour at room temperature, I incubated with 
primary antibodies overnight at 4oC. Primary antibodies are described in Table 4.1. I 
then washed the membranes with TBST and incubated with appropriate secondary 
antibody for 1 hour at room temperature. Following a TBST wash, I developed 
membranes using the Pierce ECL Substrate Kit (Cat. No. 32106; Pierce) and a 
quantitative gel imaging station (Bio-Rad ChemiDoc System). I utilized ImageLab 
software to record and analyze membrane chemiluminescence. 
Statistical analysis of the data 
I used GraphPad Prism 6.0 software for statistical analyses of the results. To 
compare two independent groups, I determined the means ± S.E.M. or ± S.D. (as 
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indicated) and utilized the Student’s t-test. Differences with a p <0.05 were considered 
statistically significant. 
RESULTS 
Oral cavity carcinogenesis after 4-NQO treatment 
All mice survived the 10-week 4-NQO treatment, consistent with our previous 
studies23, 24, 26. To confirm that transgenic (TG) ALDH1a2 was being induced during 
this phase of treatment, we took ear snips from each 4N+Dox mouse at the 10-week 
time point, isolated RNA, and performed RT-PCR analysis for TG ALDH1a2 
transcripts. We detected TG ALDH1a2 transcripts in KRT/ALDH mice, indicating that 
co-treatment with 4-NQO did not interfere with our dox-inducible system in this tissue 
(Supplemental Figure 4.1).  No TG ALDH1a2 was detected in 4N+Dox KRT mice 
(Supplemental Figure 4.1).  
We elected to use dox-treated KRT mice as the control group in our 
experiments rather than untreated KRT/ALDH mice for several reasons. First, this 
strategy controls for any off-target effects of long term low-dose doxycycline (2 
mg/mL for 21 weeks). In addition, unlike untreated KRT/ALDH mice, there is no risk 
of ectopic ALDH1a2 expression in KRT mice due to the inherent leakiness of Tet-On 
systems. The use of dox-treated KRT mice as a control in Tet-On transgenic mouse 
experiments is well-documented and this strategy was employed in the original 
research on KRT mice conducted by Nguyen, et al29.  
We observed the development of multifocal precancerous and cancerous 
lesions, primarily on the dorsal side of the tongue, in both KRT and KRT/ALDH mice 
during the weeks following 4N+Dox treatment. By 11 weeks post-treatment, 10% of 
the 4N+Dox-treated mice had died (2/20; n=1 KRT and n=1 KRT/ALDH), and many 
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mice had large visible tongue lesions, so the mice were sacrificed at this time (Figure 
4.1A). The body weights of the surviving 4N+Dox-treated KRT and KRT/ALDH mice 
did not differ from each other at the time of sacrifice (Figure 4.1B). 
RESULTS PART I: MOLECULAR CHANGES 
Endogenous ALDH1a2 expression is decreased in 4-NQO-treated mice 
ALDH1a2 expression is reduced in HNSCC patients and in human HNSCC 
cell lines (as discussed in Chapter 2 (Figures 2.1, 2.2)). We therefore investigated 
whether endogenous ALDH1a2 expression is also reduced in the 4-NQO murine 
model of OSCC carcinogenesis following carcinogen treatment. By western blot 
analysis of KRT mice we observed a ~2.4-fold decrease in ALDH1a2 protein levels in 
4N+Dox mice as compared to VC (vehicle control)+Dox mice (Figure 4.2A). This 
result is in accord with our previous data on ALDH1a2 mRNA levels published in 
Tang et al., 2014; Tang et al. assessed genome-wide transcript levels in normal mouse 
tongues and tongue SCCs induced by 4-NQO using Next-Generation Sequencing 
(RNA-Seq) analysis25. These data are now freely accessible in the Gene Expression 
Omnibus (GEO) database (accession no. GSE54246). These data show that 
endogenous ALDH1a2 transcript levels are decreased by approximately 62% in 
tongue SCCs induced by 4-NQO as compared to normal mouse tongue samples 
(Figure 4.2B). We therefore conclude that endogenous ALDH1a2 mRNA and protein 
expression is decreased during carcinogenesis in the 4-NQO mouse model of OSCC. 
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Transgenic ALDH1a2 transcript expression in KRT/ALDH mice following treatment 
with VC+Dox or 4N+Dox 
We utilized RT-PCR to verify the transcript expression of TG ALDH1a2 in 
tongues from KRT/ALDH mice following treatment. We detected TG ALDH1a2 
transcripts in both VC+Dox and 4N+Dox KRT/ALDH mice, but not in littermate KRT 
mice (Figure 4.3A,B). Interestingly, while we were able to detect TG ALDH1a2 
transcripts in all of the KRT/ALDH mice, the level of transcript expression was  
ALDH1a2 
β-actin 
All mice are K14-rtTA 
233 242 269 271 16 169 186 192 210 
VC+Dox 4N+Dox
A 
B 
Figure 4.2: Endogenous ALDH1a2 expression is decreased in mouse tongues 
during carcinogenesis in the 4-NQO murine model of OSCC. (A) Western blot 
analysis of tongues of KRT mice treated with VC+Dox (n=4 shown) or 4N+Dox (n=5 
shown). We treated mice as described (Figure 4.1). Tongues were snap frozen in 
liquid nitrogen before homogenization in final sample buffer. We incubated 
membranes with 1:100 ALDH1a2 primary antibody and 1:80,000 β-actin (loading 
control) (primary antibodies are detailed in Table 4.1). (B) Quantitative analysis of 
ALDH1a2 transcripts from RNA-Seq data obtained by Tang et al., 2014. These data 
are freely accessible in the Gene Expression Omnibus (GEO) database (accession no. 
GSE54246). FPKM, fragments per kilobase of exon model per million mapped reads. 
The data was analyzed using a Student’s t-test; ⁎⁎ indicates p<0.01 
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variable; some KRT/ALDH mice exhibited low expression of TG ALDH1a2 transcript 
(ALDH1a2low; n=7 total, n=4 VC+Dox and n=3 4N+Dox), while some exhibited high 
expression of TG ALDH1a2 (ALDH1a2high; n=11 total, n=5 VC+Dox and n=6 
4N+Dox) (Table 4.3). We quantitated the RT-PCR bands and showed that TG 
ALDH1a2 transcript levels are on average approximately 4.4-fold higher in 
ALDH1a2high mice than in ALDH1a2low mice (Supplemental Figure 4.2). In contrast, 
rtTA transcript levels were relatively constant across the entire cohort of mice, 
independent of treatment or genotype (Figure 4.3A, second row). We also observed 
variations in TG ALDH1a2 transcript expression in ear samples taken from 4N+Dox 
KRT/ALDH mice after 10 weeks of 4-NQO treatment, suggesting that this effect is not 
confined to tongues or to the 24-week end point (Supplemental Figure 4.1).  
 
Table 4.3: Relative ALDH1a2 expression in KRT/ALDH mice. 
KRT/ALDH 
  ALDH1a2low ALDH1a2high 
VC+Dox 231, 283, 293 244, 262, 270, 274, 294, 300
4N+Dox 214, 229, 230 167, 168, 193, 194, 209, 223
   
Note: ALDH1a2low and ALDH1a2high designations applied to each KRT/ALDH mouse 
based on the data shown in Figures 4.3, 4.4. 
ALDH1a2 protein levels after treatment with VC+Dox or 4N+Dox  
We used immunohistochemistry (IHC) to evaluate total (endogenous + TG) 
ALDH1a2 protein levels in the tongue epithelia at 21 weeks (see Figure 4.1A). We 
detected dark brown staining for ALDH1a2 protein in the tongue epithelia of VC+Dox 
and 4N+Dox KRT/ALDH mice but not in the epithelia of VC+Dox and 4N+Dox KRT 
mice (Figure 4.4A-C). Consistent with the RT-PCR data in Figure 4.3A, we observed 
variations in the levels of total ALDH1a2 protein in VC+Dox and 4N+Dox 
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KRT/ALDH mice, and these staining results were used to confirm the ALDH1a2high 
and ALDH1a2low designations applied to each KRT/ALDH mouse in Table 4.3. 
ALDH1a2high KRT/ALDH mice exhibited large regions of dark brown staining for 
ALDH1a2 protein, while ALDH1a2low mice showed scattered ALDH1a2-positive 
cells (Figure 4.4B,C) (additional images of ALDH1a2 protein expression in 
ALDH1a2high KRT/ALDH tongue epithelia are shown in Figure 4.5 and Supplemental 
Figure 4.3). Both the VC+Dox and 4N+Dox groups of KRT/ALDH mice exhibited 
variations in the levels of ALDH1a2 mRNA and protein expression; therefore, this 
variation is independent of 4-NQO treatment.  
AL
DH
1a
2 A
b 
VC+Dox 4N+Dox
20
0X
 
10
0X
 
A KRT
Figure 4.4: Expression of endogenous ALDH1a2 protein in tongues of KRT mice 
and endogenous plus exogenous (TG) ALDH1a2 protein in tongues of KRT/ALDH 
mice treated with VC+Dox or 4N+Dox. Tongues were fixed, embedded, sectioned, 
and stained with anti-ALDH1a2 (1:200; antibody details provided in Table 4.1). (A) 
ALDH1a2 staining of VC+Dox and 4N+Dox KRT control mice. Images were taken at 
100X and 200X, scale bar represents 200µm and 100µm, respectively. We analyzed 
one tongue section per mouse (n=19 KRT). The fields shown are representative of n ≥6 
fields taken of each section. Left column: mouse #254; right column: mouse #195. 
(B,C) Pictured on the following page.  
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Figure 4.4 (continued): (B) ALDH1a2 staining of VC+Dox KRT/ALDH mice. Left 
column: mouse #231; right column: mouse #274. (C) ALDH1a2 staining of 4N+Dox 
KRT/ALDH mice. Two different 4N+Dox ALDH1a2high KRT/ALDH mice are shown to 
convey some of the different staining patterns we observed. Left column: mouse #214; 
middle column: mouse #167; right column: mouse #223. Images were taken at 100X 
and 200X, scale bar represents 200µm and 100µm, respectively. We analyzed one 
tongue section per mouse (n=18 total KRT/ALDH). The fields shown are representative 
of n ≥6 fields taken of each section. KRT/ALDH mice were sorted into ALDH1a2high 
and ALDH1a2low groups based on the results in (B) and (C) in conjunction with RT-
PCR results as shown in Figure 4.3A (Table 4.3).  
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ALDH1a2 protein in tongue epithelia of VC+Dox and 4N+Dox ALDH1a2high 
KRT/ALDH mice was not homogeneous in its distribution. Regions of dark brown 
staining directly adjoin regions of no detectable staining in both treatment groups 
(Figure 4.4B,C). This effect is more pronounced in 4N+Dox ALDH1a2high KRT/ALDH 
mice; at 200X magnification, it is possible to find fields in the tongue epithelia of 
some 4N+Dox ALDH1a2high KRT/ALDH mice with no dark brown staining for 
ALDH1a2. We did not observe any 200X fields of VC+Dox ALDH1a2high KRT/ALDH 
tongue epithelia without any dark brown staining for ALDH1a2. In total, these data on 
ALDH1a2 mRNA and protein levels illustrate that there is notable variation in 
ALDH1a2 expression between KRT/ALDH mice in each treatment group, as well as 
within each ALDH1a2-positive tongue epithelium. 
Endogenous K14 Expression in VC+Dox and 4N+Dox KRT and KRT/ALDH mice 
Endogenous cytokeratin 14 (K14) is a type II intermediate filament protein normally 
expressed in the basal layer of the squamous epithelium30. Numerous studies have 
found that the expression of K14 and other keratins is altered upon malignant 
transformation of human epithelial cells31, 32. Chu et al. observed high K14 expression 
throughout the epithelium in the vast majority (>90%) of cases of human SCC, 
regardless of the grade of differentiation or site of origin33. Previous research 
conducted in our lab by Tang et al. revealed that K14 exhibits altered expression in the 
tongue epithelia of 4-NQO-treated mice23. While K14 is normally expressed only in 
the basal epithelial layer, he observed that K14 is expressed in the suprabasal layers in 
addition to the basal layer of the tongue after 4-NQO treatment23.  
 We used IHC to stain for endogenous K14 protein in tongue sections of 
VC+Dox and 4N+Dox KRT and KRT/ALDH mice.  In our Tet-On transgenic mouse 
system, rtTA expression is driven by a truncated human K14 promoter (Figure 3.1). 
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Therefore the expression pattern of endogenous K14 would inform us as to the 
probable localization of rtTA in the tongue epithelia of KRT and KRT/ALDH 
transgenic mice. We observed that K14 is expressed only in the epithelial basal layer 
in the tongues of VC+Dox mice (Figure 4.5A(i), A(v)). In the tongue epithelia of 
4N+Dox mice with dysplasia and SCC, we observed K14 expression in the suprabasal 
layers in addition to the basal layer of the tongue epithelium (Figure 4.5A(ii-iv), A(vi-
viii)). In addition, some adjacent, quasi-normal fields of tongues from 4N+Dox mice 
did exhibit basal layer-only expression of K14 (Figure 4.5A(ii), data not shown). We 
did not observe any difference in K14 staining between KRT and KRT/ALDH mice. In 
total, these results are consistent with the K14 staining patterns in 4-NQO-treated mice 
previously reported by Tang et al.  
We compared the expression pattern of K14 protein to the expression pattern 
of ALDH1a2 protein in KRT/ALDH mice by staining adjacent tongue sections for 
ALDH1a2 (Figure 4.5B). Consistent with the results presented in Figure 4.4C, we 
observed regions with high and low total ALDH1a2 protein expression within the 
tongue epithelia of 4N+Dox KRT/ALDH mice (presence or absence of dark brown 
stain; Figure 4.5B). However, in adjacent sections stained for K14, there were no 
fields of the tongue epithelium without brown staining for K14 (Figure 4.5A(vi-viii)). 
This result suggests that endogenous K14 and exogenous (TG) ALDH1a2 are 
differentially expressed in bitransgenic KRT/ALDH mice.  
Effect of exogenous TG ALDH1a2 expression on the extent of EZH2 expression in 
tongue epithelia after treatment with VC+Dox or 4N+Dox 
 In the experiments presented in Chapter 3 we observed that inducing ectopic 
ALDH1a2 reduced EZH2 protein levels in the tongue epithelium (Figure 3.7). EZH2 
is a methyltransferase that carries out the trimethylation of lysine 27 and lysine 9 of  
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Figure 4.5: Cytokeratin 14 (K14) protein expression in VC+Dox and 4N+Dox 
KRT and KRT/ALDH mice. Mice were treated with dox (2 mg/mL) plus 4-NQO (100 
μg/ml) (4N+Dox) or dox plus vehicle control (VC+Dox) as described. Tongues were 
fixed, embedded, sectioned, and stained with 1:100 anti-K14 or 1:200 anti-ALDH1a2 
(primary antibody details provided in Table 4.2). (A) K14 staining in tongues from 
KRT mice (i-iv) and KRT/ALDH mice (v-viii). (B) ALDH1a2 staining in matched, 
adjacent sections of tongues from the KRT/ALDH mice shown in A(v-viii). Mouse 
number and pathology are as follows: A(i) #275, normal; A(ii,iii) #169, moderate to 
severe dysplasia; A(iv) #210, invasive SCC; A(v) & B(i) #262, normal; A(vi,vii) & 
B(ii,iii) #194, moderate to severe dysplasia; A(viii) & B(iv) #193, superficially 
invasive SCC. All fields are representative of n≥8 fields analyzed per tongue section. 
We analyzed n=4 mice per group. 
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histone 3 (H3K27me3, H3K9me3) and functions as a transcriptional regulator as a part 
of the Polycomb repressive complex 2 (PRC2)34. EZH2 is overexpressed in numerous 
cancers, including HNSCC, and has emerged as a potential therapeutic target35, 36. We 
used IHC to stain for EZH2-positive cells in the tongue epithelia of VC+Dox and 
4N+Dox KRT and KRT/ALDH mice. We then used ImageJ software (National 
Institutes of Health) to quantify the percent of the basal and suprabasal layers of the 
tongue epithelium that stained positive for EZH2. Compared to the VC+Dox mice, the 
4N+Dox mice exhibited more cells that stained for EZH2 protein in the tongue 
epithelia (in terms of percent positive area; Figure 4.6A,B,C). There was a trend 
towards increased EZH2 staining as the histopathology becomes more severe (Figure 
4.6B). In addition, total EZH2 staining was decreased by approximately 13% in 
4N+Dox ALDH1a2high KRT/ALDH mice compared to 4N+Dox KRT mice (p=0.0408; 
Figure 4.6C). This result suggests that exogenous ALDH1a2 expression during 4-
NQO-induced oral cavity carcinogenesis reduces the number of EZH2-positive cells in 
the tongue epithelium.  
TG ALDH1a2high inversely correlates with vimentin expression in 4-NQO-treated mice 
 Vimentin is a type III intermediate filament protein expressed by mesenchymal 
cells, and is well-characterized as a marker of epithelial-mesenchymal transition 
(EMT)37. Numerous studies of human epithelial carcinomas (including breast cancer, 
prostate cancer, and HNSCC) have found that vimentin expression correlates with 
tumor invasion and poor prognosis38. In studies of HNSCC, decreased ALDH1a2  
activity or expression was correlated with increased expression of vimentin both in 
tumor cells in vitro, and in tumors in xenograft experiments in vivo21. We therefore 
investigated whether this inverse relationship is observed when TG ALDH1a2 is 
overexpressed in 4N+Dox KRT/ALDH mice. Using IHC, we evaluated vimentin  
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Figure 4.6: EZH2 protein in tongue epithelia of KRT and ALDH1a2high KRT/ALDH 
mice following treatment. Mice were treated with dox plus 4-NQO (4N+Dox) or dox plus 
vehicle control (VC+Dox) in the drinking water as described. Tongues were fixed, 
embedded, sectioned, and stained with anti-EZH2 (1:200; antibody details provided in 
Table 4.2). We stained one section per mouse, and images shown are representative of n≥10 
fields imaged per section (A). In total, we stained sections from n=8 KRT mice and n=9 
KRT/ALDH mice. (i-iv) EZH2 staining of n=4 KRT mouse tongues. (v-viii) EZH2 staining 
of n=4 KRT/ALDH mouse tongues. Mice were treated as indicated. Each row of images 
represents two mice of an equivalent pathologic grade and treatment. Mouse number and 
pathology are as follows: (i,v) #281, 262, normal; (ii,vi) #192, 207, mild dysplasia; (iii,vii) 
#169, 194, moderate to severe dysplasia; (iv,viii) #195, 223, invasive SCC. All of the 
KRT/ALDH mice pictured are ALDH1a2high. All images taken at 200X, scale bar represents 
100 µm. (B,C) Quantification of the percent area of the tongue epithelium that stained 
positive for EZH2 protein. Positive area was quantified using ImageJ software (National 
Institutes of Health) and plotted as a percentage of the total tongue epithelium area present 
in each field. (B) Mean percent positive area of each 4N+Dox mouse pictured in (A). Bars 
represent the mean±SEM of 4 separate fields analyzed per mouse. (C) Mean percent 
positive area of 4N+Dox KRT and KRT/ALDH mice represented in (ii-iv) and (vi-viii). Bars 
represent the mean±SEM of 4 separate fields analyzed per mouse, n=3 mice analyzed per 
group. 
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protein expression in tongues of 4N+Dox KRT and ALDH1a2high KRT/ALDH mice of 
various histopathologic grades (Figure 4.7A). Because vimentin expression is low in 
the normal squamous epithelium and is increased in SCC (especially invasive SCC), 
we stained the tongue sections from the mice of each group that presented with the 
most advanced histopathology and grade (n=4 KRT, n=4 KRT/ALDH: n=1 KRT/ALDH 
ALDH1a2low and n=3 KRT/ALDH ALDH1a2high)38. We then used ImageJ software to 
analyze the intensity of the stain and the percent of each field that stained positively 
for vimentin. We found that 4N+Dox KRT tongues had more staining for vimentin 
protein (approx. 2.5-fold more positive area, p=0.0073; approx. 1.14-fold greater 
average stain intensity, p=0.0223) compared to those from 4N+Dox ALDH1a2high 
KRT/ALDH mice (Figure 4.7B,C,D,E). We also observed that the n=1 ALDH1a2low 
KRT/ALDH mouse had higher vimentin protein expression than the n=3 ALDH1a2high 
KRT/ALDH mice (both area and intensity of stain; Figure 4.7A,B,C). These data 
indicate that higher TG ALDH1a2 in 4N+Dox-treated mice results in reduced 
vimentin expression, and support an inverse relationship between ALDH1a2 and 
vimentin in HNSCC. 
DISCUSSION PART I: MOLECULAR CHANGES 
Aberrant expression of key members of the RA signaling pathway is frequently 
observed during HNSCC carcinogenesis7, 39. ALDH1a2, an enzyme that synthesizes 
intracellular RA, is decreased at both the mRNA and protein levels in human HNSCC 
patients and cell lines (Chapter 2, Figures 2.1, 2.2)20. In addition, we found that 
endogenous ALDH1a2 mRNA and protein levels are reduced in 4-NQO-treated mice 
compared to mice treated with vehicle control (Figure 4.2). Other members of the RA 
signaling pathway that exhibit reduced mRNA and protein levels in HNSCC include 
lecithin:retinol acyltransferase (LRAT), CRABP2, RARβ, and RARγ40-44. Conversely,  
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Figure 4.7: Vimentin expression is decreased in 4N+Dox ALDH1a2high 
KRT/ALDH mice. KRT and KRT/ALDH mice were treated with dox (2 mg/mL) and 
4-NQO (100 μg/ml) (4N+Dox) in drinking water for 10 weeks and then maintained 
on dox alone before sacrifice at 21 weeks (Figure 4.1A). Tongues were fixed, 
embedded, sectioned, and stained with anti-Vimentin (1:200; antibody details 
provided in Table 4.2). We stained tongue sections from the n=8 mice that presented 
with the most severe pathologies. We stained one section per mouse, and images 
shown are representative of n≥10 fields imaged per section (A). (a-d) Vimentin 
staining of n=4 4-NQO-treated KRT mouse tongues. (e-h) Vimentin staining of n=4 4-
NQO-treated KRT/ALDH mouse tongues. Each mouse is pictured next to to n≥1 mice 
from the other group of the same treatment and pathology. Mouse number and 
pathology are as follows: (a) #169, moderate to severe dysplasia, (e) #168, severe 
dysplasia; (b) #164, SCC in situ with superficial invasion, (f) #193, superficially 
invasive SCC, (g) #229, superficially-invasive SCC, SCC in situ; (c,d) #195 and 
#210, invasive SCC, (h) #223, invasive SCC. All of the KRT/ALDH mice pictured are 
ALDH1a2high with the exception of #229 shown in (g), which is ALDH1a2low. All 
images taken at 200X, scale bar represents 100 µm. The inset in each picture is 
approximately 2.5X the digital magnification of a region of interest. (B,C) 
Quantification of vimentin staining in tongues from mice shown in (A) using Image J 
software. We analyzed n≥5 fields of a stained tongue section from each mouse. Each 
field was analyzed for total positively-stained area (in pixels) (B), and for the mean 
pixel intensity (arbitrary units) (C). Mouse #300 is a representative VC+Dox for 
reference. The other 8 mice were all treated with 4N+Dox. The results are presented 
as mean ±SEM. (D,E) Compilation of quantification of vimentin staining in tongues 
of 4N+Dox KRT and KRT/ALDH mice shown in (B,C). These results are 
representative of data from n=5 fields per mouse, and are graphed as mean ±SEM. All 
statistical analysis was conducted using GraphPad Prism 6.0 software. The results are 
presented as mean ±SEM. The data were analyzed using a Student’s t-test, and 
differences with a p < 0.05 were considered statistically significant (marked with an 
asterisk).  
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cytochrome P450 26A1 (CYP26A1), which catalyzes the first step of RA degradation, 
is increased in HNSCC45, 46. These changes illustrate that RA signaling is often 
reduced in HNSCC, which is thought to greatly contribute to tumor development7. A 
better understanding of the roles of these proteins in HNSCC carcinogenesis could 
provide valuable information for future prevention and treatment of HNSCC and other 
human cancers. 
To study the role of ALDH1a2 in HNSCC carcinogenesis we utilized 
transgenic mice with inducible TG ALDH1a2 expression in the tongue epithelium 
(K14-rtTA/TRE-ALDH1a2; KRT/ALDH) (Chapter 3, Figures 3.2-3.4). At the end of 
the 21-week treatment we observed that within the tongue epithelia of 4N+Dox 
ALDH1a2high KRT/ALDH mice there is notable variation in ALDH1a2 protein 
expression: populations of cells with dark brown staining for ALDH1a2 directly 
adjoin regions in which there is no observable increase in staining compared to control 
tongues from KRT mice (Figure 4.4C).  
We hypothesize that this result can be partly explained by recent research 
conducted in our laboratory by Tang et al.47. Tang et al. used a cell lineage tracing 
approach in K14-CreERTAM/ROSA26 mice to identify and track K14+ epithelial stem 
cells in the normal tongue and in tongues undergoing 4-NQO treatment. By observing 
X-Gal(+) clonal cell populations the authors concluded that in the normal tongue, 
K14+ basal epithelial cells are long-lived and undergo asymmetric division to generate 
differentiated progeny and maintain homeostasis (Supplemental Figure 4.3). However, 
following treatment with 4-NQO, there were fewer X-Gal(+) clonal cell populations, 
and the X-Gal(+) clonal cell populations were larger than those in control tongues 
(Supplemental Figure 4.3A-C). In addition, 4-NQO treatment resulted in increased 
apoptosis and proliferation of basal cells, as measured using a TUNEL assay and Ki67 
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labeling, respectively (data not shown)47. These data indicate that 4-NQO treatment 
causes some basal stem cells to die and that the surviving neighboring stem cells 
compensate for this through symmetric division, resulting in the disappearance of 
some X-Gal(+) clonal cell populations and the expansion of others (Supplemental 
4.3E). In the present study, some of the ALDH1a2-positive regions in 4N+Dox 
ALDH1a2high KRT/ALDH mice display characteristics similar to the horizontally-
expanded X-Gal(+) clonal populations observed by Dr. Tang (Figure 4.4C, middle and 
right columns; Supplemental Figure 4.3D)47. This suggests that these regions of high 
or low ALDH1a2 expression originate from one or more basal layer progenitor cells 
and expand laterally to replace regions of basal cells killed by 4-NQO.  
In addition, we observed that VC+Dox and 4N+Dox KRT/ALDH mice varied 
significantly in the degree of ALDH1a2 mRNA and protein levels (ALDH1a2high vs. 
ALDH1a2low groups; Figures 4.3, 4.4). We do not yet have an explanation for this 
variance; possibilities range from differences in mouse water intake to differences in 
epigenetic regulation at the sites of the genetic copies of the ALDH1a2 transgene in 
the genomes of the individual mice.  
As epithelial cells undergo EMT, they lose their adhesion and polarization 
properties and become more prone to invasion and migration48. EMT is believed to 
play a key role in cancer metastasis, as it enables the cells to leave the primary tumor 
site and initiate metastases in distant sites49, 50. Many proteins and signaling networks 
contribute to the process of EMT. One such protein is EZH2, which regulates gene 
expression as a central component of the PRC2; recent research has found that 
overexpression of EZH2 is a frequent event in HNSCC and correlates with advanced 
clinical stage, tumor size, poor prognosis, and lymph node metastases51, 52. EZH2 has 
therefore been proposed as a novel biomarker as well as a molecular target for future 
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targeted therapies in HNSCC patients53. In HNSCC, EZH2 negatively regulates E-
cadherin, an epithelial marker, and positively regulates vimentin, a mesenchymal 
marker; loss of E-cadherin expression and gain of vimentin expression are key factors 
in EMT52. In HNSCC patients, reduced E-cadherin expression and enhanced vimentin 
expression correlate with higher incidence of metastasis50. In HNSCC cell lines, 
knockdown of EZH2 using siRNA induced E-cadherin expression, reduced vimentin 
expression, and inhibited cell migration and invasion51, 52.  
In the present study, we found that the expression of TG ALDH1a2 during 4-
NQO-induced carcinogenesis reduced the expression of EZH2 and vimentin in mouse 
tongues (Figures 4.6, 4.7). Numerous previous studies have found that RA negatively 
regulates PRC2 activity, and treatment of nasopharyngeal carcinoma cells with RA 
decreases EZH2 expression34, 54. Because ALDH1a2 catalyzes the intracellular 
synthesis of RA, we hypothesize that ALDH1a2 expression reduces EZH2 expression 
by increasing RA synthesis and signaling; in turn, it is plausible that reduced EZH2 
expression then decreases vimentin expression. However, the underlying molecular 
mechanisms of the downregulation of EZH2 and vimentin by ALDH1a2 remain to be 
elucidated. Our results are in agreement with recent work by Siedensaal et al., which 
showed that inhibition of ALDH1a2-RAR signaling in HNSCC cell lines in vitro and 
knockdown of ALDH1a2 in xenograft experiments in vivo promoted a mesenchymal-
like phenotype characterized by increased vimentin expression, enhanced migration in 
vitro and accelerated tumor growth in vivo21. However, our current study is the first to 
provide a link between ALDH1a2 and EZH2, and taken together, these results indicate 
that ALDH1a2 may inhibit tumor cell EMT, invasion, and metastasis during HNSCC 
carcinogenesis. 
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RESULTS PART II: PHENOTYPIC CHANGES 
Lesion severity and multiplicity in 4N+Dox KRT and KRT/ALDH mice  
All of the surviving 4N+Dox mice (n=18 total, n=9 KRT and n=9 KRT/ALDH) 
exhibited observable gross lesions on the tongue (grade ≥1, Figure 4.8A). In contrast, 
mice treated with VC+Dox (n=19 total, n=10 KRT and n=9 KRT/ALDH) exhibited no 
visible gross lesions (grade 0, data not shown). We analyzed the severity (grade) and 
numbers (multiplicity) of gross lesions of 4N+Dox mice in a blinded manner. We 
found no statistical difference in the average lesion grade or average lesion 
multiplicity between KRT mice and KRT/ALDH mice (Figure 4.8B,E).  The scatter 
plots in Figure 4.8C,F illustrate the distribution of lesion severity and multiplicity 
within each group. After 4N+Dox treatment, approximately 22% of KRT mice 
presented with low-grade lesions (grade <2; n=2), ~56% with medium-grade lesions 
(grade 2-3; n=5), and ~22% with high grade lesions (grade 4-5; n=2) (Figure 4.8D). 
Approximately 44% of KRT/ALDH mice exhibited low-grade lesions (grade <2; n=4), 
~22% exhibited medium-grade lesions (grade 2-3; n=2), and ~33% exhibited high-
grade lesions (grade 4-5; n=3) (Figure 4.8D). Therefore, following 4-NQO treatment, 
KRT/ALDH mice had greater incidence of low-grade lesions (grade <2) and lower 
incidence of medium-grade lesions (grade 2-3) compared to KRT mice. The rate of 
high grade lesions was comparable between the two groups (n=2 KRT vs. n=3 
KRT/ALDH), however the only grade 5 lesion observed was on the tongue of a KRT 
mouse. See Supp. Fig. 4.1 for the grade and multiplicity of each 4N+Dox mouse. 
Because we observed notable variation in the degree of ALDH1a2 mRNA and 
protein expression in KRT/ALDH mice (Figures 4.3, 4.4), we analyzed lesion severity 
and multiplicity relative to ALDH1a2 expression (Figure 4.9). By separating the 
4N+Dox KRT/ALDH group into ALDH1a2high and ALDH1a2low subgroups, we  
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observed an interesting pattern among the n=6 ALDH1a2high mice. 50% of the 
ALDH1a2high mice presented with low lesion grade and lower multiplicity (grade <2, 
lesion number <12; n=3 mice), 50% with high grade and higher multiplicity (grade 4-
5, lesion number ≥18; n=3), and none with medium grade or multiplicity (grade 2-3, 
lesion number 12-17) (Figure 4.9A-C). This suggests that high expression of 
ALDH1a2 during 4-NQO-induced carcinogenesis can have two disparate effects: 
overexpression of ectopic ALDH1a2 can result in either a less severe phenotype or a 
more severe phenotype.  
Histopathological analysis of tongues from mice subjected to the 4-NQO murine 
model of carcinogenesis 
 In order to evaluate the histopathology of the tongue epithelia of 4N+Dox 
mice, a blinded board-certified pathologist analyzed one H&E-stained tongue section 
from each 4N+Dox mouse. Each tongue section was characterized according to the 
observed stage of oral carcinogenesis; these stages include normal, hyperplasia, 
dysplasia (mild, moderate, severe), and carcinoma (carcinoma in situ/superficial SCC  
Figure 4.8: Lesion development following 4-NQO treatment. KRT and KRT/ALDH 
mice (n=10, each group) were treated with dox (2 mg/mL), and 4-NQO (100 µg/mL) 
for 10 weeks (4N+Dox). All mice were then switched to dox alone (2 mg/mL) until 
sacrifice at 21 weeks. (A) Representative images of gross tongue morphology 
observed at the time of sacrifice (images taken at 10X). All mice were graded in a 
blinded manner on a scale of 1-5 (5 being the most severe) depending on the 
observable gross lesion severity on the tongue surface. Pictured is a tongue 
representative of each grade. There was only one tongue that received a grade of 5, 
which is shown twice to better illustrate the size of the lesion (bottom right panels). 
Esophagi were also photographed at this time. (B-D) Grading of observable tongue 
lesions of KRT and KRT/ALDH mice treated with 4N+Dox. (D) Graphical 
representation of the percentage of each group of mice (KRT or KRT/ALDH) that 
presented with each lesion grade. Graph represents n=9 total surviving mice per 
group. (E,F) Counting of gross observable lesions on the tongues of 4N+Dox KRT 
and KRT/ALDH mice. In all panels, error bars represent mean±SEM. Statistical 
analysis conducted using GraphPad Prism 6.0 software.  
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Figure 4.9: Lesion severity and number in ALDH1a2high and ALDH1a2low 
KRT/ALDH mice following 4-NQO treatment. Mice were treated with dox (2 
mg/mL) and 4-NQO (100 µg/mL) for 10 weeks before being switched to dox alone (2 
mg/mL) for another 11 weeks. Tongues were dissected and photographed immediately 
following sacrifice. The grossly visible lesions on the whole tongues were counted and 
graded in a blinded manner. KRT/ALDH mice were designated ALDH1a2high (n=6) and 
ALDH1a2low (n=3) according to ALDH1a2 mRNA and protein expression as 
determined by RT-PCR and IHC, respectively (Figures 4.3,4.4, Table 4.3). (A) Lesion 
severity observed in 4-NQO-treated mice. All mice were graded in a blinded manner 
on a scale of 1-5 (5 being the most severe). (B) Number of observable tongue lesions 
of mice treated with 4-NQO. (C) Lesion severity of each mouse graphed relative to 
observed lesion number. Each data point represents an individual mouse. Bars in (A,B) 
represent mean, determined using GraphPad Prism 6.0 software.  
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or invasive SCC). Representative pictures of each histopathologic stage are shown in 
Figure 4.10. Of the 4N+Dox mice, we found that 56% of KRT mice (n=5) and 44% of 
KRT/ALDH mice (n=4) exhibited histopathology indicative of low-risk of oral 
carcinogenesis (normal, hyperplasia, mild-moderate dysplasia), and that 44% of KRT 
mice (n=4) and 56% of KRT/ALDH mice exhibited histopathology indicative of high 
risk of oral carcinogenesis (severe dysplasia, carcinoma in situ/superficial SCC, 
invasive SCC) (Supplemental Table 4.1)24. Because only one 7µm section per mouse 
tongue was analyzed, these histopathology classifications are not necessarily 
representative of the whole tongue phenotype. For example, KRT mouse #11-186, 
which was graded as having a lesion severity of 3 and presented with a medium-large 
gross lesion on the left dorsal side of the tongue, was evaluated as having a normal 
histopathology (Supplemental Figure 4.1). Histopathological analysis of additional 
tongue sections from each mouse could yield additional insights on differences 
between the KRT and KRT/ALDH mice. In the present study we have chosen to focus 
on lesion grade as a readout of disease severity, as it is representative of the whole 
tongue. Histopathologic stage was used to categorize the tongue sections themselves 
and inform the analysis as described in Part I of this chapter.  
DISCUSSION PART II: PHENOTYPIC CHANGES 
 Previous research in our lab has explored the role of RA signaling in the 4-
NQO murine model of OSCC carcinogenesis. Transgenic mouse experiments in which 
LRAT was constitutively overexpressed specifically in oral basal epithelial cells 
revealed that this overexpression makes the cells more sensitive to carcinogenesis 
induced by 4-NQO26. In addition, treatments with exogenous retinoids including RA 
(100 μg/kg body weight and 1 mg/kg body weight), bexarotene (a RXR agonist), and 
CD1530 (a RARγ selective agonist) were found to reduce incidence of oral cavity  
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Figure 4.10: Histopathology of carcinogenesis in the 4-NQO murine model of 
OSCC. Immediately following sacrifice, mouse tongues were dissected, fixed (4% 
PFA overnight at 4°C), embedded, sectioned (7µm), and stained with hematoxylin 
and eosin (H&E). One tongue section from each 4-NQO-treated mouse was analyzed 
by a certified pathologist as described in the Materials and Methods (n=18 mice total; 
n=9 KRT and n=9 KRT/ALDH. Representative pictures of pathology, images were 
taken at 200X and scale bar represents 100µm. (i) normal; (ii) mild hyperplasia with 
marked hyperkeratosis; (iii) moderate dysplasia; (iv) severe dysplasia; (v) 
superficially-invasive, SCC in situ; (vi) invasive SCC. A representative image from 
the only mouse classified as having hyperplasia is shown in Supplemental Figure 4.4. 
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carcinogenesis induced by 4-NQO as measured by the multiplicity and severity of 
gross observable lesions24, 25. In contrast, we did not observe a significant change in 
the mean lesion severity or multiplicity in KRT/ALDH mice compared to KRT control 
mice, though we did observe a trend towards increased incidence of low grade tumors 
(grade <2) (Figure 4.8). There are numerous potential explanations for why ectopic 
ALDH1a2 expression did not decrease mean lesion severity and grade in this study 
like treatment with exogenous retinoids did in previous studies. First, VC+Dox and 
4N+Dox KRT/ALDH mice varied significantly in the level of ALDH1a2 mRNA and 
protein induction by dox (ALDH1a2high vs. ALDH1a2low groups; Figures 4.3, 4.4). In 
addition, strong ALDH1a2 protein expression in ALDH1a2high KRT/ALDH mice was 
present in only certain regions of the tongue epithelium (Figure 4.4), as discussed in 
Discussion Part I. It is worth speculating that the effect of exogenous ALDH1a2 
expression on gross lesion development would be more pronounced in transgenic mice 
with less intra-group and intra-tongue variation in ALDH1a2 expression. Lastly, 
4N+Dox KRT/ALDH mice, which have a genetic background of 50/50 C57Bl/6/FVB, 
exhibited accelerated tumor development as compared to previous experiments in 
which mice of other genetic backgrounds were treated with the same concentration of 
4-NQO (100 µg/mL)23, 24, 26, 27, 55. In xenograft experiments by Seidensaal et al., 
knockdown of ALDH1a2 in HNSCC cells prior to injection resulted in accelerated 
tumor growth but did not change the overall incidence of tumors21. Therefore, 
additional experimentation with KRT/ALDH mice using an earlier treatment endpoint 
or consistent monitoring of tumor growth over time might yield additional insights. 
 We observed two distinct sub-populations of 4N+Dox ALDH1a2high 
KRT/ALDH mice (n=6 total): mice with high grade/high multiplicity (n=3) and mice 
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with low grade/low multiplicity (n=3) (Figure 4.9C). This result suggests that 
expression of ectopic ALDH1a2 during carcinogenesis can have two disparate effects. 
We hypothesize that this may be because these sub-populations differ in their 
expression of proteins downstream of ALDH1a2 in the RA signaling pathway. 
Researchers recently observed that HNSCC patients with tumors with high ALDH1a2 
protein expression (ALDH1a2high) have a more favorable clinical outcome than 
patients with ALDH1a2low tumors, but only in the presence of CRABP2 
(ALDH1a2highCRABP2high)21. In contrast, patients with ALDH1a2highCRABP2low 
tumors had a worse overall survival probability comparable to patients with 
ALDH1a2low tumors21. In the absence of transport protein CRABP2, the intracellular 
RA synthesized by ALDH1a2 is free to be shuttled by a different lipid transporter, 
such as fatty acid binding protein 5 (FABP5). Unlike CRABP2, which preferentially 
delivers RA to RAR/RXR heterodimers for downstream signaling, FABP5 favors 
activation of RAR/peroxisome proliferator-activated receptor (PPAR) heterodimers56. 
While RAR/RXR signaling is known to promote differentiation, cell cycle arrest, 
apoptosis, and/or inhibition of cell growth, RAR/PPAR signaling promotes the 
expression of pro-survival factors such as survivin or components of the PDK-1/Akt 
pathway56, 57. Thus, RA signaling (and synthesis of RA by ALDH1a2) can activate 
opposing signaling pathways and have diverse effects on cell growth depending on the 
status of CRABP2, FABP5, and nuclear receptor expression. Indeed, it is hypothesized 
that expression of RARβ is a major contributing factor to how HNSCC patients 
respond to treatment with classical retinoids12. It is therefore feasible that the high 
grade/high multiplicity sub-population of ALDH1a2high KRT/ALDH mice have a high 
FABP5/CRABP2 ratio or reduced expression or activity of one or more RARs; this 
hypothesis could be addressed by analyzing the relative expression of other members 
of the retinoid signaling pathway in each ALDH1a2high KRT/ALDH mouse.  
115 
 
CONCLUSIONS 
Based on these findings, we speculate that ALDH1a2 suppresses tumor cell 
EMT during OSCC carcinogenesis in vivo. Future experiments will investigate 
whether this observation translates to inhibition of distant metastases, which would be 
of clinical significance. We also observed that expression of endogenous ALDH1a2 is 
reduced following carcinogen-induced OSCC (Figure 4.2). These data, taken together 
with our data on HNSCC cell lines as described in Chapter 2, provide evidence that 
ALDH1a2 has tumor suppressive functions in HNSCC. Interestingly, our results also 
suggest that enhanced ALDH1a2 expression during OSCC carcinogenesis can have 
two disparate effects on lesion severity and multiplicity (Figure 4.9). Future 
experiments will determine if this phenomenon is due to the relative activity of the 
proteins downstream of ALDH1a2 in the RA signaling pathway (Figure 1.2).  
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SUPPLEMENTARY DATA 
ALDH1a2 TG 
ALDH1a2 TG 
36B4 
36B4 
162      164     165     169     186     192    195     210     211    219
161      167     168     193     194     209     214     223     229      230
K
R
T 
K
R
T/
A
LD
H
 
4N+Dox
Supplemental Figure 4.1: Verification of ALDH1a2 transcript induction after 
4-NQO treatment. Ear snips were collected from all mice at the close of the 10-
week dox plus 4-NQO treatment (4N+Dox) (n=20, n=10 KRT and n=10 
KRT/ALDH). We conducted RT-PCR analysis of transgenic ALDH1a2 transcript, 
and confirmed that transgenic ALDH1a2 (ALDH1a2 TG) was induced in 
KRT/ALDH mice and not KRT mice. 36B4 represents the loading control gene. 
This result suggests that ALDH1a2 induction by doxycycline was not impeded by 
co-treatment with 4-NQO. Faint ALDH1a2 TG bands were just visible in the lanes 
for KRT/ALDH mice #214 and 229. The variation of intensity of ALDH1a2 
induction in KRT/ALDH mice is addressed more thoroughly in Figures 4.3 and 4.4. 
All primer sequences are provided in Table 4.2. 
Mouse # 
Mouse # 
Supplemental Figure 4.2: Quantification of the ALDH1a2 TG bands observed 
in KRT/ALDH tongues in Figure 4.3A,B using Image J software. Values are 
normalized to 36B4. Mice were sorted into ALDH1a2high and ALDH1a2low groups 
based on the results in Figure 4.3 and in conjunction with IHC results as shown in 
Figure 4.4. See Table 4.3. Bars represent mean±SEM; **** indicates p<0.0001. 
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Supplemental Figure 4.3 (adapted from Tang et al., 2013): Expansion of clonal 
cell populations following 4-NQO treatment. (A-C) K14-CreERTAM/ROSA26 mice 
received tamoxifen treatment (4mg/mouse/day) by intraperitoneal injections on two 
consecutive days four weeks prior to the start of treatment. Mice (n≥3 per group) were 
then treated with 4-NQO (100 µg/mL) or vehicle control for various times (as 
indicated). After dissection, tongues were stained with X-Gal as described. (A) Whole-
mount X-Gal staining of mouse tongues. Images taken at 8X. (B) H&E-stained 
sections from X-gal-stained tongues. Images taken at 200X, scale bar represents 50 
μm. (C) Quantification of the number of X-Gal(+) populations on the dorsal side of 
the tongue and the areas (ii) of the biggest X-Gal(+) populations on the dorsal side of 
each tongue. (D) Images of tongue sections from n=2 4N+Dox ALDH1a2high 
KRT/ALDH mice stained with 1:200 ALDH1a2. Images taken at 200X, scale bar 
represents 100 μm. (E) Model of tongue epithelia homeostasis generated by Tang et al. 
Under normal conditions (left panel) basal stem cells undergo asymmetric division 
(red arrows). Treatment with 4-NQO (right panel) results in the death of some basal 
stem cells and the expansion of others via symmetric division (blue arrows). 
Supplemental Figure 4.4: Additional histopathology. Immediately following 
sacrifice, mouse tongues were dissected, fixed (4% PFA overnight at 4°C), embedded, 
sectioned (7µm), and stained with hematoxylin and eosin (H&E). One tongue section 
from each 4-NQO-treated mouse was analyzed by a certified pathologist as described 
in the Materials and Methods (n=18 mice total; n=9 KRT and n=9 K14-rtTA/TRE-
ALDH1a2). Representative pictures of pathology of mouse #11-165: hyperplastic 
squamous mucosa with acute and chronic inflammation. Images were taken at 200X 
and scale bar represents 100µm. 
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CHAPTER FIVE 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
K14-rtTA/TRE-ALDH1a2 murine model of inducible ALDH1a2 expression 
We have developed the first murine model for inducible ALDH1a2 expression. 
In our Tet-On system, ALDH1a2 is inducibly and reversibly expressed in certain 
squamous epithelial tissues: the tongue, skin, and esophagus (Figures 3.2, 3.3). Because 
of the importance of endogenous RA signaling in both normal and disease states of the 
epithelium, such a model will be a valuable experimental system for future experiments.  
The effect of TG ALDH1a2 expression on retinoid signaling 
One of the goals of this project was to determine how overexpression of ectopic 
ALDH1a2 affects RA signaling in the epithelium. Preliminary data from human SCC 
cell lines infected with ALDH1a2-containing retrovirus suggest that ALDH1a2 
overexpression increases the expression of certain other RA signaling pathway genes in 
transformed keratinocytes (see Appendix, Figure A.1). We also observed that TG 
ALDH1a2 increased CRABP2 protein levels and decreased EZH2 protein levels in the 
tongue epithelia of K14-rtTA/TRE-ALDH1a2 (KRT/ALDH) mice (Figure 3.5B). These 
data indirectly evidence that ectopic ALDH1a2 stimulates RA signaling, however future 
work should be done to confirm this directly. While we were ultimately unsuccessful in 
using LC-MS to measure retinoid levels following TG ALDH1a2 induction by dox due 
to technical issues, we are optimistic that these issues can be resolved in future LC-MS 
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experiments (see Appendix, Figures A.2, A.3). Ideally, this future work will delineate 
the effects of ectopic ALDH1a2 expression on total intracellular RA levels, which 
would greatly inform our results as well as the field of retinoid synthesis and 
metabolism. 
The effect of TG ALDH1a2 on EZH2 and PRC2 activity 
 We were intrigued to observe that TG ALDH1a2 decreases EZH2 protein levels 
in the tongue epithelia of KRT/ALDH mice treated with dox (Figures 3.7, 4.6). We 
intend to follow up on this observation with numerous additional analyses. Endogenous 
EZH2 is a methyltransferase that functions as a core component of the Polycomb 
Repressive Complex 2 (PRC2), and catalyzes the trimethylation of lyine 27 on histone 
H3 (H3K27me3)1. We therefore will evaluate the levels of H3K27me3 and the levels of 
other members of PRC2 (such as Suz12 and Eed) in dox-treated KRT/ALDH mice to 
further our understanding of how TG ALDH1a2 affects the functions of EZH2 and 
PRC2.  
EZH2 plays a critical role in the differentiation of embryonic basal epithelial 
progenitor cells2. We therefore plan to investigate whether the decreased EZH2 protein 
levels in tongue epithelia of dox-treated KRT/ALDH mice are associated with changes 
in the differentiation of the basal stem cell population. To assess this, we will look at 
markers of epithelial terminal differentiation – such as loririn and filaggrin – in dox-
treated KRT and KRT/ALDH transgenic mice.  In addition, we will continue our ongoing 
experiments with K14-CreERTAM+/-/ROSA26+/-/K14-rtTA+/-/TRE-ALDH1a2+/- 
quadruple-transgenic mice, as described in the Appendix. In this work, we are utilizing 
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a lineage-tracing approach to evaluate how TG ALDH1a2 expression affects the tongue 
stem/progenitor cell profile. These experiments will illuminate how TG ALDH1a2 
repression of EZH2 expression affects basal epithelial cell differentiation in the tongue.  
ALDH1a2 as a putative tumor suppressor in head and neck cancer 
We have demonstrated that endogenous ALDH1a2 mRNA and protein 
expression is reduced in human HNSCC compared to normal tissue, cultured human 
HNSCC cell lines compared to a non-transformed line, and the tongues of carcinogen-
treated mice compared to control-treated mice in the 4-NQO murine model of OSCC 
(Figures 2.1, 2.2, 4.2). Together, these results indicate that decreased ALDH1a2 levels 
are a common event in HNSCC. Furthermore, there is a logical pathogenic connection 
between loss of ALDH1a2 expression and HNSCC carcinogenesis since ALDH1a2 
synthesizes intracellular RA, a known signaling molecule for growth arrest, apoptosis, 
and differentiation3. We have also shown that ectopic ALDH1a2 expression decreases 
the proliferation and colony formation of human SCC cells (Figures 2.4, 2.5). Together 
these data indicate that ALDH1a2 acts as a tumor suppressor in HNSCC.  
ALDH1a2 as an inhibitor of tumor cell migration and metastasis 
 We observed that ectopic ALDH1a2 decreased known markers of EMT – 
vimentin and EZH2 – in the tongue epithelia of 4-NQO-treated mice (Figures 4.5, 4.6). 
This is an intriguing finding which suggests that ALDH1a2 inhibits tumor migration 
and metastasis during OSCC carcinogenesis. However more research should be 
conducted to confirm this hypothesis. This could be investigated using cellular 
migration and invasion assays of control- and ALDH1a2-infected SCC cell lines in vitro 
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and analyzing the cell lines for expression of EMT markers. In addition, by injecting 
the SCC cell lines into oral cavities of immunocompromised mice, we could test the 
ability of ALDH1a2-infected lines to develop SCCs and metastases in vivo4.  
In Chapter 4, we utilized a 4-NQO-induced murine model of OSCC in which 
mice are administered 100 µg/mL 4-NQO (plus dox) in the drinking water for 10 weeks. 
Following 10 weeks of 4-NQO treatment, mice are switched to drinking water 
containing dox alone and monitored for cancerous lesion development. Though mice in 
this model develop lesions that are histologically and molecularly similar to those 
observed in human OSCC, they generally do not develop lymph node metastases, which 
is a common feature of the human disease5. In 2013, Li et al. reported that treating mice 
with a higher dose of 4-NQO (200 µg/mL) for a longer period of time (20 weeks) 
resulted in a high rate of lymph node metastases6. Therefore in order to evaluate whether 
ectopic, TG ALDH1a2 inhibits metastasis development in 4N+Dox KRT/ALDH mice, 
we could conduct additional experiments in which KRT and KRT/ALDH mice are treated 
with higher dose 4-NQO (plus dox) for a longer period of time and assessed for regional 
lymph node metastases.  
Lastly, we would also like to investigate whether TG ALDH1a2 affects the 
expression of E-cadherin in addition to vimentin. While vimentin is mesenchymal 
marker, E-cadherin is an epithelial marker, and both of these proteins are well-
characterized as markers of EMT. Increased vimentin expression and decreased E-
cadherin expression are observed in HNSCC patient tumors, and associate with poor 
prognostic factors such as recurrence, reduced overall survival, and lymph node 
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metastases7. In addition, knockdown of EZH2 in HNSCC cell lines FaDu and SNU1041 
increased E-cadherin expression and decreased vimentin expression8. We therefore 
intend to evaluate the E-cadherin protein levels in the tongue epithelia of our VC+Dox 
and 4N+Dox KRT and KRT/ALDH mice, to further characterize how ectopic ALDH1a2 
affects EMT in this tissue during 4-NQO-induced carcinogenesis.  
ALDH1a2: a putative drug target? 
Increasing intracellular RA signaling through a means other than application of 
exogenous retinoids is still for the most part an unexplored and unexploited avenue for 
HNSCC therapy. Studies have shown that the cellular localization of RA, and the 
efficacy of stimulated gene expression, can differ depending on whether RA is added 
externally or is generated endogenously. For example, inhibition of RA catabolism to 
increase intracellular RA was shown to be effective in breast cancer cells, whereas 
application of exogenous RA was not9. To date the limited efficacy of exogenous 
retinoid treatment is largely attributed to rapid metabolism – both on a cellular level via 
CYP26A1, and on an organismal level via the liver9. An ALDH1a2-based therapy could 
potentially exhibit different metabolic properties and be more efficacious and/or less 
toxic than delivery of exogenous RA. Furthermore, the ALDH family of enzymes is 
amenable to activation via small molecules, which can be identified via adaptation of 
an already established high throughput screen, making development of a therapeutic 
strategy to increase ALDH1a2 activity in tumors a future possibility10. Lastly, there is 
evidence that ALDH1a2 and other key members of the RA signaling pathway exhibit 
reduced expression in HNSCC due to promoter hypermethylation11, 12. Therefore, 
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should future experimentation on ALDH1a2 in HNSCC prove promising, combination 
therapy of an ALDH1a2-activator and a DNA methyltransferase inhibitor could be an 
attractive chemotherapeutic strategy. 
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APPENDIX 
 
CHANGES IN RA TARGET GENES IN SCC-25 CELLS AS MEASURED BY 
RT-PCR 
  In our experiments described in Chapter 2, we analyzed the phenotypic effects 
of transgenic (TG) ALDH1a2 overexpression in cultured human SCC cell lines. We 
also carried out analysis of transcript levels of known RA target genes following 
retroviral infection of SCC-25 cells with pQC (empty vector) or pQC-ALDH1a2. The 
pQC-ALDH1a2 vector drives constitutive overexpression of ALDH1a2 (Supplemental 
Figure 2.1). These RT-PCR analyses, repeated n=2 times, provided preliminary 
evidence that overexpression of TG ALDH1a2 increased transcript expression of 
retinoic acid receptor γ (RARγ) and cytochrome P450 enzymes CYP26A1 and 
CYP26B1 in SCC-25 cells (Figure A.1). Cells infected with the empty vector and 
treated with exogenous RA (1 µM) (+pQC +RA) were used as a positive control. We 
also observed increased CYP26A1 and CYP26B1 transcript levels in ALDH1a2-
infected SCC-9 cells (n=2, data not shown).  
The retinoic acid receptors, including RARγ, are bound and activated by RA to 
initiate changes in gene transcription that control many key cellular processes1. 
Cytochrome P450 family 26 (CYP26) enzymes metabolize RA and are highly inducible 
by RA in many cellular contexts, including in keratinocytes2, 3. Therefore these 
preliminary results suggest that overexpression of TG ALDH1a2 is sufficient to increase 
RA signaling in this transformed oral keratinocyte line. Future experiments will confirm 
these results in this and other HNSCC cell lines, and delineate the effect of ectopic 
ALDH1a2 expression on other known RA signaling genes (e.g. RARβ2) compared to 
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treatment with exogenous RA. Such results would be highly informative to the study of 
retinoid signaling in the context of epithelial carcinomas. 
 
 
Table A.1: Primer sequences used for RT-PCR 
Gene Forward Primer  (5'-3') 
Reverse Primer  
(5'-3') 
Product 
Size 
ALDH1a2 TG gacttgtagcagctgtcttcact tcacccatttctctcccatttcc 160 bp 
CYP26A1 gaggggagagcggctggaca agcaacccgaaaccctcctgg 292 bp 
CYP26B1 tgggcttcccgctcatcgga ctcacgaggtggtgctcgcc 181 bp 
RARγ aatgacaagtcctctggctaccac cagatccagctgcacgcggtggtc 393 bp 
HPRT1 tgaggatttggaaagggtgt aatccagcaggtcagcaaag 155 bp 
 
TG ALDH1a2 
HPRT1 
RARγ 
CYP26A1 
CYP26B1 
SCC-25 
Figure A.1: mRNA expression of RA signaling genes in infected SCC-25 cells. 
SCC-25 cells were infected overnight with either empty vector (pQC) or a vector 
driving constitutive expression of ALDH1a2 (pQC-ALDH1a2, Supplemental Figure 
2.1) and selected 7-10 days with puromycin. Cells were then plated for experiments 
and treated with vehicle control (DMSO) or 1µM RA for 7 days. We then harvested 
cells and performed RNA isolation according to the manufacturer’s protocol. RT-
PCR protocol is described in the Materials and Methods of Chapters 2-4. TG 
ALDH1a2 results shown here are representative of n≥3 biological repeats. RARγ, 
CYP26A1 and CYP26B1 RT-PCR results shown here are representative of n=2 
biological repeats. HPRT1 was used as a loading control. All primers used in this 
figure are described in Table A.1.  
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THE EFFECTS OF ECTOPIC (TG) ALDH1A2 EXPRESSION ON RETINOID 
LEVELS IN THE STRATIFIED SQUAMOUS EPITHELIUM 
 
Endogenous ALDH1a2 plays a critical role in retinoid signaling and 
metabolism, as it catalyzes the synthesis of intracellular RA1, 2. Therefore, we 
anticipated that the induction of exogenous (TG) ALDH1a2 using our Tet-On 
expression system would result in increased intracellular all-trans retinoic acid (RA) in 
target tissues. In addition, absolute quantitation of RA following expression of TG 
ALDH1a2 would provide direct evidence that ALDH1a2 overexpression increases RA 
signaling through increased RA synthesis. In preliminary experiments in our lab, using 
reverse phase high-performance liquid chromatography (HPLC), we could not detect 
retinol or RA in mouse tongue and skin samples from either K14-rtTA (KRT) or K14-
rtTA/TRE-ALDH1a2 (KRT/ALDH) mice treated with dox for 72 hrs (data not shown). 
Consequently, we next tried using liquid chromatography-mass spectrometry (LC-MS), 
which has a lower limit of detection3. These experiments are detailed below. 
MATERIALS AND METHODS 
Liquid chromatography-mass spectrometry (LC-MS) analysis of retinoid levels 
 We treated K14-rtTA(+/-)/TRE-ALDH1a2(+/-) (KRT/ALDH) mice and K14-
rtTA(+/-) (KRT) littermate mice with dox for 72 hours before sacrifice. All mice were 
from the #11 line. We dissected whole tongue (60-100 mg each) and skin (~100 mg 
each) from each mouse, and snap froze and weighed each tissue sample before 
homogenization in 500 µL PBS. As an internal control of extraction efficiency, we 
added 25 µL of a 100 µM stock of retinyl acetate, which is not present endogenously in 
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these tissues. We then extracted retinoids as previously described4, 5. Briefly, we added 
350 µL of acetonitrile:butanol (50:50, v/v) to each sample and vortexed for 45 seconds. 
We then added 300 µL of a saturated K2HPO4 solution (~1.3 Kg/L), vortexed again, and 
centrifuged 10 minutes at 14,000 rpm. The upper organic layer was collected, dried 
down, and placed under argon before shipping to the Metabolite Profiling Core Facility 
at the Whitehead Institute for Biomedical Research (affiliated with the Massachusetts 
Institute of Technology) for LC-MS analysis. In our first LC-MS experiment, each 
individual tissue was analyzed separately (i.e. the retinoid extract of n=1 mouse tongue 
= 1 sample analyzed by LC-MS). In our second LC-MS experiment, we pooled the 
tissue retinoid extracts in triplicate (i.e. the retinoid extracts from n=3 mouse tongues = 
1 sample analyzed by LC-MS) before drying them down for shipping. Retinoic acid and 
retinol were measured using an RP-Amide column with a gradient of water/0.1% formic 
acid and acetonitrile/0.1% formic acid, as previously described3. Retinyl palmitate and 
retinyl acetate were measured using a C18 column, as previously described6. Retinoid 
levels were normalized to starting tissue weight and retinyl acetate detection, as 
indicated. Work at the Whitehead Institute was conducted by Dr. Elizaveta Freinkman. 
Dr. Freinkman, the director of this facility, left the Whitehead Institute in the fall of 
2016 and there was a search for a new director.  
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RESULTS 
The effect of ectopic ALDH1a2 expression on retinoid levels in the stratified squamous 
epithelium 
 Using LC-MS as described in the Materials and Methods, we measured the 
levels of RA in the tongues and skin of n=3 KRT/ALDH mice and n=3 KRT mice treated 
with dox for 72 hours (6 tongue and 6 skin samples analyzed, 1 tongue and 1 skin per 
mouse). We also analyzed the levels of retinol and retinyl palmitate (a retinyl ester), to 
ascertain how dox induction of TG ALDH1a2 affected the retinoid pathway and overall 
retinoid status of target cells. In our initial LC-MS run we could not detect retinyl 
palmitate in the majority of the samples (detected in 3/6 tongue and 1/6 skin samples; 
data not shown). In addition, we detected very low levels of RA in both tongue and skin 
samples (ranging from 0.0008 to 0.066 pmol/mg tissue; RA in one KRT/ALDH tongue 
sample was undetectable) (Figure A.2). Furthermore, both RA and retinol levels were 
variable within each group of mice, complicating further analysis (Figure A.2).  
We therefore conducted a larger experiment in which we treated n=18 mice (n=9 
KRT/ALDH, n=9 KRT) for 72 hours with dox, and extracted retinoids from tongue and 
skin tissue as before. We then pooled the retinoid extracts from n=3 individual tissue 
samples to generate larger samples for analysis (i.e. the n=9 tongues from each group 
were pooled in triplicate to generate 3 separate samples for LC-MS). Unfortunately, due 
to a technical failure at the facility, RA levels were undetectable in all samples, 
including the standard curve samples. This experiment could not be repeated in the fall 
of 2016 because of the departure of Dr. Freinkman. However we were able to detect  
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Figure A.2: LC-MS of retinoids in the tongues and skin of n=6 dox-treated KRT 
and KRT/ALDH mice. Six 6-8 week-old #11 line mice (n=3 KRT, n=3 KRT/ALDH) 
were treated with dox for 72 hrs before sacrifice and tissue dissection. Whole 
tongues (~60-100 mg) and skin (~100 mg) were weighed, snap frozen, and 
homogenized in PBS. Retinoids were extracted according to standard protocol, dried 
down, and shipped on dry ice to the Whitehead Institute for  LC-MS analysis. (A,B) 
Analysis of tissue retinoic acid levels. (C,D) Analysis of tissue retinol levels. All 
results shown are normalized to starting tissue weight and retinyl acetate 
concentration. Error bar represents ±SEM as calculated by GraphPad Prism 6.0 
software. 
A B 
C D 
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retinyl palmitate in all of the tongue and skin samples, and we detected no statistical 
differences in the average retinyl palmitate levels of dox-treated KRT and KRT/ALDH 
mice (Figures A.3A,B). Retinol levels also exhibited no significant differences in the 
mean in the tongue and skin samples (Figures A.3C,D). However, retinol levels in the 
tongue and skin samples from KRT/ALDH mice exhibited greater variation than those 
from KRT mice; using an F test to compare variances, we found that there was a 
statistical difference in the variance (p=0.0003) of tongue retinol levels in KRT/ALDH 
mice compared to KRT mice.  
 
DISCUSSION 
We investigated how induced expression of TG ALDH1a2 modulates 
intracellular retinoid levels using LC-MS. Ultimately we were unable to obtain a 
conclusive result for RA levels in the tongues and skin of KRT and KRT/ALDH mice. 
Future experiments with these mice will seek to achieve this, as RA levels are a key 
measurement in determining how expression of TG ALDH1a2 affects intracellular RA 
synthesis and signaling. Using HPLC, researchers in our lab were previously able to 
detect tongue retinol levels of 0.06±0.02 pmol/mg in control-fed wild type mice 
(normalized to starting tissue weight)7. In our first LC-MS experiment (1 tongue = 1 
sample analyzed), we detected tongue retinol levels of 1.393±0.2086 pmol/mg 
(normalized to starting tissue weight and retinyl acetate concentration) (Figure A.2). In 
our second LC-MS experiments (3 tongues = 1 sample analyzed) we detected tongue 
retinol levels of 0.1045±0.0002 (normalized to starting tissue weight and retinyl acetate  
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Figure A.3: LC-MS of retinoids in the tongues and skin of n=18 dox-treated 
KRT and KRT/ALDH mice. Eighteen 6-8 week-old mice (n=9 KRT, n=9 
KRT/ALDH; all #11 line) were treated with dox for 72 hrs before sacrifice and tissue 
dissection. Whole tongues (~60-100 mg) and skin (~100 mg) were weighed, snap 
frozen, and homogenized in PBS. Retinoids were extracted according to standard 
protocol, pooled in triplicate, dried down, and shipped on dry ice to the Whitehead 
Institute for  LC-MS analysis. (A,B) Analysis of tissue retinol levels. (C,D) Analysis 
of tissue retinyl palmitate levels. All results shown are normalized to starting tissue 
weight and retinyl acetate concentration. Error bar represents ±SEM as calculated 
by GraphPad Prism 6.0 software. 
A B 
C D 
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concentration) (Figure A.3). Therefore our second experiment, in which we used tissue 
samples pooled in triplicate, was more consistent with previous data on retinoid levels 
in these tissues (Figure A.3).  
We did not observe any statistical difference in the mean levels of retinyl 
palmitate or retinol (Figure A.2, A.3). Of course, we would not expect a difference in 
retinyl palmitate or retinol since the levels of these retinoids are much higher than those 
of RA in most tissues7, 8. However, with respect to tongue retinol levels, there was a 
statistically significant difference in the variance between KRT mice and KRT/ALDH 
mice. This was unexpected since each sample analyzed was a combination of three 
whole tongues from different mice. While the meaning of this result is inconclusive, it 
could suggest that ALDH1a2-inducing KRT/ALDH mice exhibit greater variation in 
tongue vitamin A status as compared to control mice. Future experiments will seek to 
clarify the effect of ectopic TG ALDH1a2 expression on retinoid levels in these tissues. 
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USING A CELL LINEAGE TRACING APPROACH TO INVESTIGATE THE 
EFFECT OF TRANSGENIC ALDH1A2 ON STEM CELL DIVISION 
 
Previously, researchers in our lab have utilized K14-CreERTAM/ ROSA26 
transgenic mice to identify and track K14+ epithelial stem cells1, 2. Using this transgenic 
expression system, we are able to permanently mark stem/progenitor cells in the mouse 
tongue epithelia and visualize clonal cell populations using X-gal staining. In my 
experiments, we observed that increased transgenic (TG) ALDH1a2 decreased EZH2 
protein expression in normal and 4-NQO-treated tongue epithelia (Chapters 3, 4). EZH2 
is a known orchestrator of gene expression in the differentiation of embryonic epithelial 
stem cells3. We therefore wanted to investigate whether inducible TG ALDH1a2 
expression affects the stem/progenitor profile in normal and carcinogen-treated tongue 
epithelia. 
We crossed a K14-rtTA+/-/TRE-ALDH1a2+/- mouse with a K14-CreERTAM+/-
/ROSA26+/- mouse to generate a K14-CreERTAM+/-/ROSA26+/-/K14-rtTA+/-/TRE-
ALDH1a2+/- line. The pups resulting from this cross were genotyped for the presence of 
each of the four transgenes using RT-PCR as previously described (Chapter 3, 4)1. Mice 
from this line that possess all four transgenes will have ALDH1a2 expression (following 
doxycycline (dox) treatment) and LacZ expression (following tamoxifen treatment) 
specifically in the basal layer of the epithelium.  
We treated n=22 mice of various genotypes. N=6 were positive for all four 
transgenes, n=5 positive for K14-CreERTAM+/-/ROSA26+/-, n=3 positive for K14-rtTA+/-
/TRE-ALDH1a2+/-, and the remainder positive for other gene combinations that will not 
result in any TG ALDH1a2 expression or positive X-gal staining. All mice received 
tamoxifen (4mg/mouse/day) by intraperitoneal injections on two consecutive days two 
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weeks prior to the start of treatment. Mice were then treated with vehicle control plus 
dox (2 mg/mL; Sigma) (VC+Dox) or 4-NQO (100 100 µg/mL; Sigma) plus dox (2 
mg/mL) (4N+Dox) for 10 weeks. We sacrificed mice at the 12 week time point, and 
carried out X-gal staining as previously described1, 2.  
We aimed to analyze the resulting blue signal and compare: a) VC+Dox K14-
CreERTAM+/-/ROSA26+/-/K14-rtTA+/-/TRE-ALDH1a2+/- and K14-CreERTAM+/-
/ROSA26+/- mice, which would reveal how TG ALDH1a2 affects the stem/progenitor 
profile in non-transformed tongues, and b) 4N+Dox K14-CreERTAM+/-/ROSA26+/-/K14-
rtTA+/-/TRE-ALDH1a2+/- and K14-CreERTAM+/-/ROSA26+/- mice, which would reveal 
how TG ALDH1a2 affects the stem/progenitor profile in tongues undergoing 4-NQO-
induced carcinogenesis. Analysis has been complicated by genotyping errors which 
were discovered after sacrifice. These errors resulted in n<3 mice in some of the key 
treatment groups. Future experiments will remedy this, and currently analysis of this 
experiment is still underway. Representative images of X-gal stained tongues from 
some of the groups are shown in Figure A.4. 
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Figure A.4: Representative photomicrographs of whole mount X-gal-stained 
tongues to visualize a representative population of stem cells. (A) VC+Dox-
treated mice (n=3) positive for K14-CreERTAM/ROSA26 (ALDH1a2-); (B) 4N+Dox-
treated mice (n=3) positive for K14-CreERTAM/ROSA26 (ALDH1a2-); (C) VC+Dox-
treated mouse (n=1) positive for K14-CreERTAM/ROSA26/K14-rtTA/TRE-ALDH1a2 
(ALDH1a2+); (D) 4N+Dox-treated mouse (n=1) positive for K14-
CreERTAM/ROSA26/K14-rtTA/TRE-ALDH1a2 (ALDH1a2+) (two views shown). 
Magnification, ×4. 
149 
 
 
REFERENCES 
 
1. Tang XH, Scognamiglio T, Gudas LJ. Basal stem cells contribute to squamous cell 
carcinomas in the oral cavity. Carcinogenesis. 2013;34: 1158-1164. 
2. Osei-Sarfo K, Tang XH, Urvalek AM, Scognamiglio T, Gudas LJ. The molecular 
features of tongue epithelium treated with the carcinogen 4-nitroquinoline-1-oxide and 
alcohol as a model for HNSCC. Carcinogenesis. 2013;34: 2673-2681. 
3. Ezhkova E, Pasolli HA, Parker JS, et al. Ezh2 orchestrates gene expression for the 
stepwise differentiation of tissue-specific stem cells. Cell. 2009;136: 1122-1135. 
 
